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ABSTRACT
Patients with end stage renal disease (ESRD) often require hemodialysis treatments in
which blood’s water and dissolved solutes undergo diffusion and convection by exposure
to an extracorporeal membrane. The leading cause of death in this population is
cardiovascular, and how hemodialysis is prescribed alters total sodium balance, a critical
determinant of cardiovascular health. We performed retrospective and prospective
analysis of data from patients in the Southwestern Ontario Regional Hemodialysis
Program. An increased Dialysate sodium (Dial-Na+) to Pre-dialysis plasma sodium (PreNa+) concentration difference (DPNa+) leads to adverse clinical outcomes in
hemodialysis patients. The post- to pre-dialysis plasma sodium difference (PPNa+)
predicts clinical outcomes equally well as DPNa+ so long as Dial-Na+ is within 3
mmol/L of Pre-Na+. Calculation of DPNa+ requires determination of the Pre-Na+,
historically thought to be stable in hemodialysis patients and thus termed “setpoint” (SP).
However, we determined that SP is modifiable by hemodialysis prescription. Finally, an
equation to predict interdialytic weight gain was created, confirming Dial-Na+, dialysis
frequency and duration to be modifiable factors affecting IDWG. Further research is
required to validate this equation prospectively, and to determine the impact of changes of
SP on cardiovascular morbidity and mortality.

KEYWORDS
Hemodialysis, end stage renal disease, end stage kidney disease, interdialytic weight gain,
cardiovascular mortality, sudden cardiac death, dialysate sodium, sodium setpoint,
diffusive sodium balance, ultrafiltration, osmotic sodium balance, quotidian hemodialysis,
nocturnal hemodialysis, home hemodialysis.
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1.0 General Introduction
Prevalence of kidney disease in the United States (U.S.) has increased by over 60 times
from 1973 to 2011.1,2 Now approximately 15% of the population is affected by kidney
disease,3-5 translating to over 4 million Canadians6 and 40 million Americans.7
Prevalence estimates have been difficult without a uniform definition of kidney disease;
fortunately, this was formalized in 2002 (Table 1.1).8
Stage

Glomerular Filtration Rate*

1
2
3
4
5
“End Stage”

> 90 mL/min/1.73 m2
60-89 mL/min/1.73 m2
30-59 mL/min/1.73 m2
15-29 mL/min/1.73 m2
<15 mL/min/1.73 m2 OR
renal replacement therapy ***

Kidney
Damage**

Prevalence
(%)

+
+/+/+/-

1.8
3.2
7.7
0.4

+/-

2.4

Table 1.1: Kidney Disease Outcomes Initiative Definition of Kidney Disease
* Glomerular Filtration Rate defined by a Serum Creatinine, as per CockcroftGault,9 Modification of Diet in Renal Disease (MDRD)10 or Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI)11 equations
** Kidney Damage may include urinary abnormality (eg. Microalbuminuria,
hematuria) or structural abnormality of the kidney
*** Renal replacement therapy may include peritoneal dialysis, hemodialysis, or
renal transplantation
Critical in the formal definition is the recognition that kidney disease exists on a
continuum, and that patients can progress from one stage to the next. Though 15% of the
population suffers from kidney disease, 2.4% (Table 1.1) have the most advanced “end
stage” 5, and many of these patients require renal replacement therapy. There are three
types of renal replacement therapy, being peritoneal dialysis (PD), hemodialysis (HD),
and renal transplantation (RTx). Hemodialysis is a process in which a patient’s blood is
exposed to a man-made dialyzer membrane to remove waste products, to restore the
proper balance of electrolytes such as potassium and phosphate, and to eliminate extra
fluid from the body. Most recent estimates suggest there are 23,188 Canadians12 and
398,861 Americans13 with Stage 5 kidney disease so severe that they require renal
replacement with hemodialysis treatments.
!

!
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Patients with all stages of kidney disease are at higher risk of cardiovascular death

than the general population.14-16 The most common cause of death in patients with end
stage kidney disease is indeed cardiovascular (Figure 1.1).2

Figure 1.1: Causes of Death in Patients with End Stage Renal Disease
Cardiovascular disease encompasses a wide spectrum of pathologies, but in end-stage
kidney disease patients using hemodialysis (ESRD-HD), up to 60% of cardiovascular
deaths are by sudden cardiac death (SCD).17 It is well established that SCD risk increases
as renal function worsens;18 Several mechanisms have been proposed, including
hemodialysis prescription,19-26 anemia and vascular access,27-31 atherosclerosis,19,32
arteriolosclerosis,33,34 volume and pressure overload.20,35-40
1.1

Hemodialysis

Of special importance in hemodialysis patients are the separate effects of volume
overload and pressure exerted upon the left ventricular output,20,35-40 which ultimately
lead to left ventricular hypertrophy41-49 and death.50,51 In conventional hemodialysis
!

!
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patents, urine output is either absent or insufficient, so hemodialysis is performed three
times a week to remove solutes and fluids. The increase in weight from the end of a
hemodialysis session to the start of the next session is called interdialytic weight gain
(IDWG) (Figure 1.2).

Figure 1.2: Interdialytic Weight Gain in Patients Undergoing Hemodialysis
Tuesdays, Thursdays and Saturdays
Overwhelming evidence suggests that, when corrected for confounding factors such as
nutritional status,52,53 increases in IDWG lead to increased morbidity and mortality in
hemodialysis patients.37,38,53-56 Thus, defining strategies that effectively control
interdialytic weight gain is of clinical importance, and likely will lead to improved
survival of hemodialysis patients.
Total body volume is regulated through sodium balance,57 and thus the major
determinant of IDWG is a patient’s total sodium balance (Equation 1.1).

Equation 1.1: Total Sodium Balance
IDWG ~ [Na+] Balance = [Na+] intake (oral or intravenous)
-

Urinary [Na+] excretion - Other (fecal/sweat) [Na+] excretion

+ [Na+] balance in hemodialysis
In hemodialysis patients, urinary [Na+] excretion is either non-existent or negligible, and
fecal and sweat sodium excretion is negligible. Thus, the [Na+] balance in a hemodialysis

!
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patient is determined by [Na+] intake (oral or intravenous) and by [Na+] balance in
hemodialysis. It is well established that dietary oral sodium restriction decreases IDWG
and left ventricular mass.58,59 Likewise, administration of intravenous sodium chloride
solution increases IDWG.60,61 However, the effect of [Na+] balance, during hemodialysis,
on IDWG, is less well understood. An understanding of the biological and physical
processes involved in hemodialysis, and their effects on total sodium balance, is therefore
essential to determine how to reduce IDWG, and ultimately, hemodialysis patient
morbidity and mortality.
Hemodialysis is a process in which a patient’s blood is exposed to a man-made
dialyzer membrane to remove waste products, to restore the proper balance of
electrolytes such as potassium and phosphate, and to eliminate excess body fluid (Figure
1.3). Blood leaves the patient (Figure 1.3- blue curved arrow) from an intravenous
catheter, into a hemodialysis machine, where it enters “pre-membrane” into the top of a
dialyzer, simultaneous to clean dialysate fluid entering the bottom of the same dialyzer.
After the waste products and excess water are removed, blood leaves the dialyzer, and is
pumped back into the patient (Figure 1.3- red curved arrow).A
As blood flows through the parallel array of small caliber cylindrical tubes in the
operational core of a dialysis machine (the dialysis “membrane”), the material walls of
the tubing are the hemodialysis membrane. The flow in each tube is approximately
parabolic in velocity profile, the fastest in the center, and slowest at the wall. The friction
between these fluid layers is known as viscosity, or less formally as “stickiness.”
Mathematically, the viscosity (η), is defined as the ratio of the fluid shear stress (τ,in Pa),
divided by the fluid shear rate (δv/δr, in s-1 ) [η = τ /(δv/δr), thus having units of Pa.s]. If
the viscosity of a fluid is independent of shear rate, then the viscosity is said to be a
Newtonian fluid. While blood does have a minor dependence of its viscosity on shear
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
A

There are many components to the standard hemodialysis machine, including heaters,
deaeration, blood tubing, blood and dialysate pumps, blood leak detector, flow meter,
conductivity cell and display, pH probes, filters, dialysis membrane, and electrical supply.
However, it is not the objective of this thesis to discuss each individual component. Instead, only
those components that have a role in sodium balance in hemodialysis are discussed. Furthermore,
the dialysis machine and components are kept relatively constant from one instrument to another.
These instruments are also kept relatively constant whether a patient performs their treatment in a
hospital, or at home. Therefore, the biophysical forces involved in hemodialysis are similar
regardless of the location of the treatments.
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rate at very low shear rates, it is considered to be Newtonian in the larger blood vessels
and within the dialysis instrumentation.
The removal of waste products and water relies upon passage of blood inside one
of thousands of hollow fibers,B with dialysate fluid moving in the opposite direction on
the opposite side (Figure 1.4). Since sodium removal during hemodialysis is critical to
the total body sodium balance, which in turn is important in cardiovascular and all-cause
mortality, a detailed understanding of all the factors that contribute to intradialytic

Figure 1.3: Hemodialysis Process
sodium balance is essential. Sodium balance during hemodialysis occurs by both
diffusion and convection.
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
B

In nephrology clinical settings, a hemodialysis hollow “fiber” is one of thousands of cylindrical
“tubes” encased within a hemodialysis “membrane.”
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Figure 1.4: Dialyzer Hollow Fibers Through Which Blood Flows.
1.1.1 Diffusion
The rate of diffusive sodium removal across dialyzer membranes is determined by Fick’s
law (Equation 1.2). In turn, Fick’s diffusion coefficient depends on a number of factors
(Equation 1.3). Combining equations 1.2 and 1.3 to determine the rate of diffusive
sodium removal leads to equation 1.4.
Equation 1.2: Fick’s Law
δn/δt = -D(A) δc/δd
Equation 1.3: Fick’s Diffusion Coefficient
D = (κΤ/6πη)(4πΝ/3Μu)1/3
Equation 1.4: Combination of Equations 2 and 3
δn/δt = (-A) (δc/δd)(κΤ/6πη)(4πΝ/3Μu)1/3
where δn/δt = the rate of movement of sodium molecules per unit time (mol/s); D =
Fick’s diffusion coefficient (m2/s); A = membrane surface area (m2); δc = concentration
difference (mol/m3) and δd = the distance a sodium molecule must move (m). κ =
Boltzman’s constant (J/K); T = absolute temperature (Kelvin); η = viscosity [Pa s]; N =
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Avogadro’s number (mol-1); M = molecular weight (g/mol); u = partial molar volume
(m3/mol).
Boltzmann’s constant (κ = 1.3806 x 10-23 m2kg/s2 deg.K.) and Avogadro’s
number (N = 6.0221 x 1023 mol-1) are known. Furthermore, dialyzed blood must be
returned to the patient at a tolerable temperature, between 35.5 and 38.0 degrees Celsius.
This prevents patient discomfort and hypothermia at low temperatures,62,63 and
intradialytic hypotension at high temperatures.64-67 Thus, there is only a narrow range for
the temperature (T), which will be simplified to 36.5 oC, or 309.65 oK. Simplifying for δn
yields Equation 1.5.
Equation 1.5: Rate of Molecular Movement During Hemodialysis
δn = (3.09 x10-14) (A) (1/Mu)1/3 (δc)
δt

η

(δd)

where δn = movement of molecules (mol); δt = time (s); A = the area of the dialyzer
membrane through which molecules move (m2); δc = concentration difference (mol/m3);
δd = the distance a sodium molecule must move (m); η = viscosity [Pa s)]; M =
molecular weight (g/mol); u = partial molar volume (m3/mol)
Thus, diffusive loss of a substance can be increased on hemodialysis by a larger
dialyzer surface area (A), a shorter distance for a molecule to travel (δd), a greater
concentration difference (δc), longer time on hemodialysis (δt), and lower blood viscosity
(η). While the design of dialysis machines and dialyzer membranes is not the goal of the
research performed for this thesis, a basic understanding is required to establish the
rationale of our research design.
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1.1.1.1 Dialyzer Area
Dialyzer membrane fiber area is a function of both fiber radius and length (equation 6).

Equation 1.6: Hemodialyzer Fiber Area
A = 2πrL
Where A = fiber surface area (m2), r = fiber radius (m),
L = fiber length (m).

1.1.1.2 Dialyzer Fiber Radius
Laminar flow of a Newtonian fluid at constant velocity can be modeled using Poiseuille’s
equation (equation 1.7). On the one hand, a small inner diameter is desirable because it
decreases the diffusive distance for solute mass transfer (equation 1.5). However, the
flow along the length of a hollow fiber is governed by the Poiseuille equation (equation
1.7), which can be rearranged for blood flow (equation 1.8).
Equation 1.7: Poiseuille’s Law
ΔP = 8(η)(Q)(L)
πr4
Equation 1.8: Blood Flow as per Poiseuille Equation
Q = ΔP/R

where R = 8ηL/πr4

Where ΔP = pressure difference between two points (P2 and P1) along a tube, η = fluid
viscosity [Pa s)], Q = volumetric flow rate (m3/s), r = radius of tube (m), R = resistance to
blood flow, L = fiber length (m)
R and r4 are inversely related; small decreases in hollow fiber radius (r) cause
large increases in flow resistance (R). In general, however, the principal resistance to
molecular movement out of dialysis tubing is the hollow fiber material itself with a minor
!
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contribution to the radial distance within the blood itself. Since blood flow rate is
constant during hemodialysis, an increase in flow resistance is matched with a large
increase in pressure drop. This pressure drop is problematic; osmotic clearance is
optimized by maximizing a dialyzer membrane’s water permeability. Therefore, high
flow resistance and associated large pressure drop associates with backfiltration of
dialysate into the blood compartment.68 This is undesirable, as backfiltration is associated
with endotoxin exposure, activation of complement, cytokines, inflammation,
malnutrition and death.69-73 Modifications in hollow fiber radius are thus limited,
reflecting a compromise between these opposing forces;74 most hollow fibers have a
relatively standard inner diameter (180-220 µm).

1.1.1.3 Dialyzer Fiber Length
Like dialyzer fiber radius, the fiber length represents a compromise between opposing
forces.74 On the one hand, an increase in diffusive capacity can be achieved by increasing
the fiber area (equation 1.3), which is dependent upon the fiber length (equation 1.6). On
the other hand, increased fiber length associates with higher flow resistance (equation
1.8) and larger pressure drop, which leads to backfiltration of dialysate into the blood
compartment.68 This is undesirable, as backfiltration leads to endotoxin exposure,
activation of complement, cytokines, inflammation, malnutrition and death.69-73 The
spectrum of hollow fiber length is thus narrow, reflecting a compromise between these
opposing forces;74 most hollow fibers have a standard length (20-24 cm).
1.1.1.4 Distance for Molecule to Travel
The distance for a molecule in blood to travel, to enter the dialysate, is determined by the
hollow fiber radius, and the fiber wall thickness (Figure 1.5). Considerations for hollow
fiber radius are discussed above (Section 1.1.1.2).
The hollow fiber thickness reflects three competing manufacturing constraints.
Firstly, the fiber wall must withstand the shear stresses of high blood flow under pressure.
Shear stress is the external force that blood acts upon the hollow fiber, parallel to the
plane in which the fiber lies. This relationship is dictated by the Poiseuille equation
!
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(equation 1.9). Shear stress against the hollow fiber wall also exerts itself against red
blood cells, making them susceptible to hemolysis. However, the risk of hemolysis in
modern hemodialysis machines is very low; thus, shear stress lies within well tolerated
physiological

limits.

improvements

in

Secondly,

complement

greater

membrane

activation,75

biocompatibility

inflammation,76

nutritional

leads

to

status,77

cardiovascular outcomes72 and mortality.72,78,79 The earliest hemodialysis membranes,
made of modified or unmodified cellulose,68 had low biocompatibility. These had a wall
thickness of 6-15 µm.80 The major constituent of these membranes was cellobiose,81
which contained a high density of hydroxyl groups that activated the alternative
complement pathway.82 Newer synthetic membranes have successfully replaced the
hydroxyl group and improved biocompatibility.
Equation 1.9: Shear Stress on Hollow Fiber Wall
τ = 4ηv/r

or

τ = 4ηQ/πr3

Where τ = shear stress on hollow fiber wall (Pa), η = blood viscosity [Pa s)],
v = average blood velocity within hollow fiber (m/s), r = fiber radius (m),
Q = blood flow rate (m3/s)
Thirdly, earlier hemodialysis membranes had a low mean pore size, limiting clearance to
only lower molecular weight toxins.83,84 On the other hand, a number of synthetic
membranes

have

been

developed,

including

polysulfone,85

polyamide,86

polymethylmethacrylate,87 polyethersulfone,88 and polyethersulfone combined with
polyamide.89 These membranes have higher water permeability and larger pore size,
permitting improved clearance of higher molecular weight proteins.85,90 Increased
clearance of higher molecular weight proteins, such as β2-microglobulin, is desirable
since it has been strongly linked to decreased incidence of neuropathy,70,91,92
cardiovascular disease93-95 and less strongly to death.94,96 In light of these manufacturing
limitations and clinical outcomes, newer hemodialysis membrane fibers tend to be
thicker-walled (> 20 µm).74
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1.1.1.5 Concentration Difference
The hemodialysis membrane concentration difference is determined by the concentration
of substance inside hollow fibers (blood) and outside the fiber (dialysate) (Figure 1.5).C
However, hemodialysis is needed thrice weekly to achieve a minimal weekly
hemodialysis clearance to achieve benefits in patient morbidity and mortality.93,97-102
Therefore, patients’ maximal blood substance concentration reflects two things, being the
duration and the rate of substance production in the interdialytic interval.

* *

! *!* *

* *
*!* *

**
*!* *

!** ***

Dialysate

!* ***
*

*! *
***

! *****

! * ***
*

!** ***

Dialysate

Figure 1.5: Schematic of Solute (*) Inside Dialyzer, Crossing Distance of Hollow Fiber
Radius and Fiber Wall to Dialysate
As the interdialytic interval duration increases, substance concentration increases.
However, changes in dialysis frequency have more pronounced impacts on the
interdialytic interval duration (Table 1.2). For example, a 50% increase in dialysis
duration from 4 to 6 hours (hemodialysis prescription 1 to 2) decreases interdialytic
interval 5.3% (38 to 36 hours), but a similar 50% increase in dialysis frequency from 4 to
6 times per week (hemodialysis prescription 1 to 3) decreases interdialytic interval 36.8%
(38 to 24 hours). More frequent hemodialysis schedules have been associated with
improved blood pressure,103,104 phosphate control,103 physical function,105 left ventricular
mass,42,103 and cardiac function.106 However, frequent (>4 sessions per week) dialysis
modalities of short (<4 hours per session) duration may in fact increase patient mortality,
compared to equal frequency but similar or longer duration.107 This is probably because
of increased dialysis access related complications108 and increased myocardial stunning
secondary to higher fluid removal rates.26,64,109-111 Thus, it is likely that both hemodialysis
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
C

Nephrologists, and indeed nephrology literature, refers to the concentration difference between
dialysate and pre-dialysis sodium, or between post- and pre-dialysis sodium as the DPNa+ or
PPNa+ “gradient.” However, the term “gradient” implies a distance factor, which is not included
in the nephrology “gradient” description. To avoid confusion, this thesis uses the term
concentration “difference” whenever possible, except in published nephrology work, which
interchangeably uses “gradient.”
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frequency and duration impact diffusive sodium balance, and thus cardiovascular and
overall patient mortality. The rate of substance production during the interdialytic period
is determined by body mass, body composition, nutritional status and general health.98
Indeed, a U shape curve is found for intradialytic urea reduction rate (x-axis) and survival
(y-axis); lower survival rates at the lower urea reduction rates reflect poor nutritional
status, anorexia, and muscle wasting, all of which are low toxin generation states.

Hemodialysis
Prescription
1"
2"
3"
4"

Frequency
(sessions per week)

Duration
(hours per session)

Interdialytic
Interval (hours)

4
4
6
6

4
6
4
6

38
36
24
22

Table 1.2: Interdialytic Interval of Four Hemodialysis Prescriptions
Maximal concentration difference requires a low concentration in the dialysate
concentration (Figures 1.3 and 1.5). For most toxins, a low pre-membrane dialysate
concentration facilitates maximal diffusive removal. However, rapid concentration shifts
during hemodialysis are associated with patient morbidity and mortality for some
substrates, requiring standard dialysate concentrations of sodium and chloride,112,113
calcium,112,114-116 potassium,117 bicarbonate and acetate,118,119 magnesium112 and glucose
(Table 1.3).120 Maximal concentration difference is supported by the countercurrent flow
of blood inside and dialysate outside of the hollow fibers (Figures 1.3 and 1.6). Blood
flow rate of 350-400 mL/min and dialysate flow rates of 500 mL/min are standard, since
higher flow rates do not significantly increase small molecular weight solute (eg. Urea)
clearance.121
1.1.1.6 Concentration Difference - Sodium
In patients without kidney disease, plasma sodium concentration is stabilized by
thirst and ADH responsive osmoreceptors located in the hypothalamus122 and the
organum vasculosum of the lamina terminalis.123,124 Plasma osmolality is calculated by
concentrations of glucose, urea and sodium (Equation 1.10).
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Equation 1.10: Calculated Plasma Osmolality
Osmolality = 2 [Sodium] + [Urea] + [glucose]
Where Sodium, urea and glucose are in mmol/L, and osmolality is in mOsm/kg.

Dialysate Constituent
Sodium (Na+)
Chloride (Cl-)
Calcium (Ca++)
Acetate
Potassium (K+)
Bicarbonate (HCO3-)
Magnesium (Mg++)
Glucose

Concentration (mEq/L)
135 to 145 mmol/L
105 mmol/L
2.5 to 3.5 mEq/L
4.0 mEq/L
1.5 to 3.0 mmol/L
33 to 38 mmol/L
0.75 mEq/L
5 to 10 mmol/L

Table 1.3: Dialysate Composition
Tight regulation maintains body fluid osmolality between 280 and 295 mOsm/kg water
by restoring plasma sodium to a patient specific “setpoint” that is stable over time (Figure
1.7).125,126,127 While the sodium setpoint is well established in people with normal renal
function,126 it was not until 1991 that it was confirmed in patients with severe
kidney disease,128 and until 2007 that is was confirmed in conventional (< 4 hour per
session) thrice weekly hemodialysis patients.129-131 However, recent evidence suggests
that thehemodialysis procedure can alter intradialytic plasma sodium concentrations.132
Moreover, previous reports of sodium setpoint stability in hemodialysis patients excluded
patients with certain comorbid illnesses, had limited plasma sodium measurements, and
only considered patients whose hemodialysis sessions were 4 hours or less in duration,
and 3 times a week. Establishing if the sodium setpoint can be modified in frequent or
longer hemodialysis is essential, since hyponatremia (low plasma sodium) has been
associated with increases in all-cause mortality.133,134 The results of previous trials that
show a survival advantage in longer hemodialysis135,136 and increased mortality in more
frequent hemodialysis107 may relate to changes in the pre-dialysis plasma sodium setpoint
(hypothesis 2.1).
!
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Blood flow;
Movement of waste product

Figure 1.6: Waste Product Concentration with Countercurrent (A)
and Concurrent (B) Flow
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Diffusive balance of sodium during hemodialysis is determined by the

concentration difference between the pre-hemodialysis plasma sodium concentration
(Pre-Na+) inside, and the dialysate sodium concentration (DialNa+) outside the
hollowfiber. In conventional thrice weekly hemodialysis patients, a positive dialysate to
plasma sodium difference (Dial-Na++ > Pre-Na+) is associated with increased blood
pressure, IDWG and cardiovascular morbidity and mortality.137-140 On the other hand, a
negative dialysate to plasma sodium difference (Dial-Na++ < Pre-Na+) is associated
with

intradialytic

hypotension, which is an independent predictor of death.132,141

Given these factors, considerable debate persists regarding the appropriateness of
personalizing dialysate sodium concentration to minimize adverse outcomes. It is
uncertain whether the dialysate to pre-dialysis plasma sodium
difference, or

the

pre-dialysis

to

post- dialysis

plasma

concentration

sodium concentration

difference is preferable to predict clinical outcomes. Furthermore, the predictive value of
dialysate, pre- and post-dialysis plasma sodium concentrations has not been evaluated in

Figure 1.7: Homeostatic Mechanism for Plasma Osmolality
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a hemodialysis population on longer or more frequent hemodialysis sessions. This has
special relevance in the design of prospective clinical trials in frequent hemodialysis
modalities, and in the clinical monitoring of such patients (hypothesis 2.2).
A hemodialysis patient’s albumin concentration influences the amount of sodium
available for diffusion. Since the anionic albumin is impermeable across hemodialysis
membranes, its negative charge leads to an electrochemical gradient, leaving less than
100% of plasma sodium available for diffusion.142 Since plasma albumin concentration is
variable, this “Gibbs-Donnan effect” may be relevant to diffusive sodium loss during
hemodialysis (hypothesis 2.3).
One of the other two components of calculated osmolality is blood glucose
(equation 1.10). In diabetes mellitus, a quantitative or qualitative insulin deficiency
prevents glucose movement into cells, leading to hyperglycemia in the extracellular
space. As hyperglycemia worsens, extracellular fluid osmolality increases (equation 1.10)
and exceeds that of the intracellular fluid, leading to movement of water out of cells into
the extracellular fluid. Plasma sodium concentration falls in proportion to the dilution of
the extracellular fluid, falling approximately 1.6 mEq/L per 5.5 mmol/L increase in blood
glucose concentration.143 It is thus plausible that the hyperglycemic milieu of diabetes
alters water and sodium balance during hemodialysis; this has not been well studied
(hypothesis 2.3).
1.1.1.7 Time on Hemodialysis
The maximal duration for conventional hemodialysis treatment was, until recently,
dictated by facility resources, and ultimately by cost; personnel costs, laboratory tests,
building maintenance, electricity, water, and administrative costs limited most patients to
a maximum of four hours per session,144-147 within one of the three hemodialysis shift
times (8 AM to 12 PM, 12:30 PM to 4:30 PM, 5 PM to 9 PM). However, when compared
to conventional hemodialysis, sessions longer than 4 hours associate with improvement
of multiple ESRD-associated conditions. While improved phosphate balance,104,148-151
renal anemia,148,152 and fertility153 are well accepted, the pathophysiology of improved
blood pressure,148,150 left ventricular hypertrophy,42,103,154,155 and mortality135,136,156,157
!
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remain controversial. There are also cost reductions with home nocturnal (6 to 8 hours
per session) hemodialysis ($36,840 to $61,220 per annum), compared to in-center
conventional (4 hours maximum per session) thrice weekly hemodialysis of four hours
($58,959 to $100,198 per annum).158-161 However, longer hemodialysis treatments are not
preferable for all patients, as the quality of life has not consistently shown differences
between hemodialysis modalities.162 Health care administrators have thus advocated for
more patients to undergo their hemodialysis treatments at home, while many
nephrologists have advocated for those home treatments to be of longer duration than 4
hours. Understanding how to optimize hemodialysis duration, within the confines of cost
and patient comfort, has the potential to improve patient morbidity and mortality.
In the London Daily Nocturnal Dialysis study,148 IDWG was higher in frequent
nocturnal (>4 sessions per week, >6 hours per session) than in short hours daily (> 4
sessions per week, < 4 hours per session) hemodialysis patients using a standard dialysate
sodium concentration of 140 mmol/L, suggesting that the time of exposure to a higher
dialysate sodium may affect IDWG. On the other hand, the Frequent Hemodialysis
Network (FHN) showed lower IDWG in the frequent nocturnal hemodialysis patients,150
but the patients in this study had variable dialysate sodium concentrations and higher
residual urinary volumes. This raised the possibility that the time of exposure to a
diffusive sodium difference was of importance to IDWG (hypothesis 2.3). Likewise,
whether residual urinary volume affected IDWG was unknown (hypothesis 2.3). Since
longer hemodialysis duration translates to longer exposure of blood to a diffusive sodium
difference (equation 1.1), this will alter IDWG and thus cardiovascular morbidity and
mortality.37,38,53-56
1.1.1.8 Viscosity
As blood viscosity increases, diffusive solute loss from blood into dialysate decreases
(Equation 1.5). The major determinants of blood viscosity are temperature,163
hematocrit164,165 and plasma protein concentration.166 Tables of blood viscosity based on
plasma albumin and blood hematocrit167,168 are accurate at low shear rates, but may not
apply to hemodialysis patients whose blood flows from and back into an arteriovenous

!

!

19!

fistula, graft or intravenous catheter during hemodialysis (Figure 1.3). However, even at
the conditions of hemodialysis, the major predictors of blood viscosity have consistently
been confirmed to be the same.169-172 Since temperature is determined by patient
hemodynamic stability and symptoms (35.5 to 38.0 degrees Celsius, see section 1.1.1,
equation 1.4), the remaining factors of importance are hematocrit and plasma protein
concentration.
Progression of kidney disease leads to an erythropoietin deficiency and
anemia.173,174 Correction of anemia is associated with increases in hematocrit, blood
viscosity and reduced diffusive hemodialysis clearance.175 However, it is other clinical
endpoints that determine current guidelines for target hemoglobin of 11.0 to 12.0 g/dL in
hemodialysis patients;176,177 considerable evidence shows that normalization of
hemoglobin >13.0 g/dL associates with increased rates of cerebrovascular disease,
myocardial infarction and death.178-183
Under most physiologic circumstances, plasma protein concentration is
determined by the most abundant plasma protein albumin. Hypoalbuminemia (<35 g/L)
is associated with cirrhosis, chronic inflammation or infection, and malnutrition.184-186
Hyperalbuminemia (>50 g/L) is much less common,187 being described in high protein
diets.188
Concerns have arisen in studies showing that blood viscosity does not consistently
decrease with decreasing vessel diameter. This Fahreus-Lindqvist effect has been
conclusively confirmed in vitro;169,189-196 when blood flows in tubes of decreasing
diameter, relative viscosity decreases.197 This effect is exaggerated once tube diameter
falls below 1.0 mm; the dialyzer hollow fiber diameter of 0.18 to 0.22 µm (section
1.1.1.2) means a ~20% reduction in relative blood viscosity, due to the Fahreus-Lindqvist
effect.195,198
Poiseuille’s law and each of its derivations (equations 1.7 and 1.8) make a number
of assumptions. Firstly, blood should be an incompressible Newtonian fluid with constant
viscosity.199 However, blood is non-Newtonian in at least two ways;195 the pressure-flow
curve is probably not linear,200,201 and shear stress is dependent on blood viscosity.
!
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However, blood viscosity still has the same predictors despite the non-Newtonian
factors;163,202 while the relationship may not be perfectly linear, equations 1.7 and 1.8 still
provide a reasonable first estimation to identify clinical factors of importance. Secondly,
there should not be acceleration of fluid in the pipe. This condition holds true for standard
hemodialysis, since a set blood flow rate from the patient maintains a constant blood flow
rate through thousands of standardized hollow dialyzer fibers.74 Thirdly, the hollow fiber
length must be substantially greater than the diameter to avoid the entrance-length
effect203,204; a length of greater than 10 times diameter is usually sufficient to overcome
this issue.205 Since the average hollow fiber radius is 180 to 220 µm (section 1.1.1.2), and
the hollow fiber length 20 to 24 cm (section 1.1.1.3), the entrance-length effect is
insignificant in hemodialysis. Fourthly and finally, blood flow through a dialyzer should
be laminar, which holds true under most circumstances.206,207 This can be confirmed by
calculation of a Reynolds number for the conditions of blood flowing through a hollow
fiber in a dialyzer for a standard hemodialysis patient.
Equation 1.11: Reynolds Number for Blood Flow in Dialyzer Hollow Fiber
Re = ρ v dH
η

!
Where Re = Reynolds number,!ρ = density (kg/m3), v = velocity (m/s), dH = diameter,
η = viscosity (Pa s).
Dialyzer fiber diameter is approximately 400 mm (section 1.1.1.2), the whole blood
density ranges from 1043 to 1057 kg/m3, and blood viscosity ranges from 3 to 4 x 10-3
(Pa s) at 37 degrees Celsius.208 Blood flow during hemodialysis is set to 400 mL/min;
assuming 12,500 hollow fibers per dialyzer and a fiber radius of 200 mm, the blood
velocity is 0.00424 m/s. Using these values, the Re of blood in a hollow fiber during
dialysis is 0.5088, well below the upper limit cutoff for laminar flow, which Reynolds
initially described to be approximately 2100.209,210
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1.1.2 Convection
Convection, also known as ultrafiltration, is the movement of water across a semipermeable membrane due to hydrostatic or osmotic pressure.211 The dialysis machine
pump exerts a negative pressure on the dialysate compartment and a positive pressure in
the blood compartment, leading to water and dissolved substances leaving the blood into
the dialysate (“solvent drag”) (Figure 1.8).212 When dialysate and patient plasma sodium
concentrations are equal, no diffusive difference is present. Intradialytic sodium loss is
then entirely dependent on negative convective balance.211
200
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Figure 1.8: Blood and Dialysate Compartment Pressures Leading to Net
Transmembrane Pressure for Convection.
Convective fluid losses during hemodialysis have pronounced impact on the
compartments that make up total body water. In an average healthy 70 kg man,
approximately 60% of body mass (42 kg) is made up of water, of which 2/3 (28 kg) is
intracellular and 1/3 (14 kg) is extracellular.213 However, if the same man becomes anuric
and hemodialysis-dependent, interdialytic weight gains lead to expansion of both
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intracellular and extracellular fluid compartments (Figure 1.9). Fluid expansion forms the
basis of clinical dry weight assessment by examining for interstitial fluid expansion
(edema) and intradialytic hypotension (Figure 1.9).213 However, it is well recognized that
a hemodialysis patient can have fluid excess
volume expansion, commonly

without

clinical

evidence of

called “silent overhydration.” 214-216 Furthermore,

Figure 1.9: Total Body Water in Healthy 70 kg Man (A) and Hemodialysis Patient With
Dry Weight of 70 kg but with 6 kg Interdialytic Weight Gain (B)
relative proportions of compartments of total body water differ significantly depending
on sex, race and body habitus (hypothesis 2.3).217 Likewise, intradialytic hypotension
occurs when increases in plasma volume from compartments outside plasma occur
slower than hemodialysis reduces plasma volume.64,218 Refilling from the interstitial fluid
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continues until 4 hours after a hemodialysis session; intradialytic hypotension is therefore
a poor marker for total body volume status. Expansion of these compartments leads to
volume overload, pressure overload,20,33,35,37-40 left ventricular hypertrophy,41-49 and
death.50,51 This effect is even more pronounced when dry weight is
assessed inaccurately as

clinically

in “silent overhydration”, since hemodialysis will return a

patient to a persistently volume overloaded state (Figure 1.10).219,220 Given the
inaccuracies of clinical volume assessment, a great deal of research has focused on
improving evaluation of hemodialysis patient’s total body water status and dry weight.
However, natriuretic peptides,221-229 diameter of inferior vena cava,222,227,230 and CRITline monitoring231-239 have limited specificity and generalizability ,220,229 and their use
may even increase mortality.236 Perhaps the most promising is the current “gold

Weight (kg)
Clinically Assessed “Dry

Weight” Patient A

Clinically Assessed “Dry Weight”Patient B
Dialysis
Session

Interdialytic
Interval

Dialysis
Session

Interdialytic
Interval

Figure 1.10: Hemodialysis Patients Oscillate from “Wet” to “Dry” State if Clinical
Assessment of Dry Weight is Accurate (A). If Dry Weight is Lower Than
Clinically Estimated (B), Patient Will Remain “Volume Overloaded” After
Hemodialysis
standard” of multiple-frequency bioimpedance spectroscopy. The resistance of body fluid
compartments can be measured, with the ratio of the resistances of the intracellular and
extracellular water reflecting the relative volume of these compartments.240 As
hemodialysis patients accumulate excess fluid in their extracellular compartment, this
ratio proves useful in the evaluation of dry weight. Considerable evidence confirms that
bioimpedance-guided volume assessment of hemodialysis patients is associated with
improved clinical outcomes,219,241-243 including mortality.219 While evaluation of these
technologies is not the objective of this document, it should be mentioned that
!

!

24!

bioimpedance has confirmed that IDWG reduction is insufficient to reduce
cardiovascular mortality if “silent overhydration” persists. This is one inherent limitation
of any clinical work designed to identify strategies to reduce IDWG.
1.2

Historical Context

“Optimal” dialysate sodium concentration has changed more frequently and for more
reasons than likely any other hemodialysis parameter.244 Early prescriptions relied on a
negative DPNa+ to increase diffusive sodium loss. A Dial-Na+ of 125 to 130 mmol/L
was standard, and osmotic loss of plasma water was promoted by using high dialysate
glucose

concentrations.244,245

However,

treatment

times

decreased

over

time,

necessitating increases in Dial-Na+ to decrease intradialytic symptoms such as
disequilibrium syndrome.246,247 A Dial-Na+ of 140 mmol/L became standardized for
patients undergoing hemodialysis thrice weekly. This increase in Dial-Na+ was further
supported when acetate-based solutions were replaced with bicarbonate-based dialysate,64
with the observation that higher Dial-Na+ were associated with less intradialytic
hypotension.53,248,249 With higher Dial-Na+, sodium removal on hemodialysis occurred by
convection only, with diffusive losses often replaced with diffusive sodium gain.
Decisions regarding Dial-Na+ became based upon minimizing patient symptoms within
the confines of having only 4 hours three times a week to assure all sodium and fluid
removal. This formed the basis of “sodium ramping,” in which higher Dial-Na+ were
used for all or part of a dialysis session.248-250 Sodium ramping successfully reduced
symptoms such as cramping, headaches and intradialytic hypotension.248,249 However,
significant increases in thirst, pre-dialysis blood pressure and interdialytic weight gain
(IDWG) raised concern that such prescriptions might exacerbate volume overload and
cardiovascular mortality.244 As such, the use of sodium ramping has largely fallen out of
favor.
As the burden of cardiovascular disease persisted in hemodialysis patients, new
strategies to counteract the chronic state of volume and pressure overload were sought.
This led to reevaluation of the standard prescription of thrice weekly hemodialysis of 3 to
4 hours each session. More frequent and longer hemodialysis are associated with
improvements in anemia control,152 calcium and phosphate balance,149,251,252 fertility,153
and volume and pressure overload.42,154,155,253,254 Indeed, nocturnal therapies associate
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with improved survival by uncertain mechanisms. This thesis examines the impact of the
present day hemodialysis prescriptions, on diffusive and convective sodium balance. This
will ultimately establish the effect of sodium balance on cardiovascular morbidity and
mortality in hemodialysis patients.
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2.0 Hypotheses
Hypothesis 2.1:
Hemodialysis of a duration greater than 4 hours or a frequency greater than 3 times
weekly has no effect on the pre-dialysis plasma sodium setpoint. This hypothesis was
evaluated retrospectively in Chapters 3 and prospectively in Chapter 7.

Hypothesis 2.2:
The dialysate to pre-dialysis plasma sodium difference and the pre- to post-dialysis
sodium plasma differences will predict clinical outcomes (blood pressure, interdialytic
weight gain, intradialytic hypotension) equally effectively in a hemodialysis population
with frequency greater than thrice weekly and session duration greater than 4 hours per
session. This hypothesis was evaluated retrospectively in Chapter 4 and prospectively in
Chapter 6.

Hypothesis 2.3:
IDWG can be predicted by several demographic and clinical factors, which each impact
sodium balance on hemodialysis. These factors may include patient factors (age, sex,
body habitus, diabetes status, dietary salt intake), laboratory factors (patient hematocrit,
plasma albumin and pre-hemodialysis plasma sodium concentration, residual renal
function), and dialysis factors (dialysate temperature and sodium concentration, dialysis
time and duration, dialysis membrane hollow fiber length and radius and wall thickness).
This was evaluated in Chapter 5.
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Chapter 3: Plasma Sodium Setpoint: Is it Constant or Changed by Hemodialysis
Prescription?

This chapter has been published as:
Thomson BK, Huang SH, Chan CT, House AA, Lindsay RM. Plasma sodium setpoint: is
it constant or changed by hemodialysis prescription? Asaio J. Sep-Oct 2013;59(5):497504.
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Introduction

Patients with normal renal function have a specific osmolality value, above which thirst is
generated and fluid ingested. This “setpoint” results in a relatively stable and
reproducible plasma sodium level over time, not only in patients without kidney disease,1
but also in patients with advanced renal disease.2 Evidence of this sodium setpoint is also
seen in thrice weekly conventional hemodialysis patients.3-5 However, hemodialysis
patients lack the mechanisms to regulate body osmolality and fluid balance. While
previous trials examining the clinical effects of different dialysate sodium concentrations
have treated pre-dialysis sodium “setpoint” as stable, this assumption has not been
confirmed in quotidian hemodialysis patients.
Lower pre-dialysis sodium “setpoint” and higher dialysate sodium concentrations
lead to important clinical outcomes such as increased blood pressure and IDWG,6-13
which may effect cardiovascular and all-cause mortality.14,15 Lower pre-dialysis plasma
sodium is independently associated with increased all-cause mortality,16,17 thus a change
in sodium “setpoint,” might need ongoing monitoring to minimize IDWG, and associated
cardiovascular morbidity and mortality.
The objective of this study was to determine if the sodium setpoint changed with
longer or more frequent exposure to the same dialysate sodium concentrations, when
patients transitioned from thrice weekly conventional hemodialysis to dialysis modalities
differing in duration and frequency.
3.2

Materials and Methods

Study Population
We performed a retrospective observational design that included all patients in the home
hemodialysis program of the Southwestern Ontario Regional Renal Program, from 1998
to December 31, 2011. A total of 87 patients, 23 still current and 64 no longer on home
hemodialysis, were included. All patients in our study were on conventional thrice
weekly hemodialysis in-center (ICHD) prior to home hemodialysis; some continued

!

!

45!

ICHD while others changed hemodialysis modality upon transferring from in-center to
home hemodialysis.
Dialysis Modality
The modality of home hemodialysis was defined by the duration of dialysis therapy, and
the frequency of treatments. Short-hours daily (SHD) hemodialysis was defined as a
minimum of 5 treatments per week, with a treatment time of 1.5 hours to 4.0 hours.
Intermittent conventional hemodialysis (ICHD) implied a maximum of 4 treatments per
week, with treatment times of 1.5 hours to 4 hours. Frequent nocturnal hemodialysis
(FNHD) was a minimum of 5 treatments per week, with a minimum treatment time of 6.0
hours. Intermittent nocturnal hemodialysis (INHD) meant a maximum of 4 treatments per
week, with a minimum treatment time of 6.0 hours. Dialysate sodium concentration was
not individualized as it was a standard 140 mmol/L for all patients at all times.
Blood sample collection
In the 50 days prior to initiation of home hemodialysis, while the patient is on in-center
thrice weekly conventional hemodialysis (ICHD-IC), pre and post dialysis blood samples
are taken every one to two weeks. Upon transition to home hemodialysis, pre and post
dialysis blood samples are routinely taken each month. Home patients are trained to take
blood from the arterial blood line at the start of dialysis and post-dialysis, using a
standard slow blood and stop dialysate method. The samples are centrifuged and then
stored and refrigerated until delivered to the local laboratory for that patient. All patient
blood tests are measured using automated and standardized methods. Of interest to this
study were pre-dialysis plasma sodium concentrations. Only outpatient blood tests were
used, to assure that the patient was at their baseline health status, so that the plasma
sodium concentration would not be confounded by acute illness.
Sodium concentration measurement
Plasma sodium concentration was measured using Beckman-Coulter LX20 Pro
Chemistry Analyzer with Ion Selective Electrodes prior to, and Roche Modular P
Chemistry Analyzer with Ion Selective Electrodes after November 4, 2008. This change
!
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was made by the London Health Sciences Center because of a need for higher volume of
laboratory testing. Both plasma Na+ concentration methods were regularly calibrated;
thus, the measurements were treated as equivalent on data analysis. Dialysate sodium
concentration was determined using online conductivity measurements built into the
Fresenius H series hemodialysis machine, which was used for all patients. Blood glucose
was not measured simultaneous to Na+ concentration; thus, plasma sodium levels were
not corrected for glucose. Dialysate Na+ concentration measurement is regularly
calibrated, to assure stability and accuracy of dialysate Na+ concentrations. Home
hemodialysis machines were evaluated and calibrated at least once, and usually twice
annually, by the program’s water engineer or one of the trained home hemodialysis
nurses.
Database Creation
Blood test results were available from the electronic patient record (PowerChart by
Cerner) of London Health Sciences Centre.
Age (years), sex, diabetes status, residual renal function (mL/min/1.73m2) and
months of renal replacement therapy prior to initiation of home hemodialysis were
determined from chart review. Residual renal function was calculated within 3 months of
conversion to home hemodialysis, as previously described.18
Weights (kg), dialysis treatment times and frequency were obtained from archived
dialysis treatment run sheets. The average values for these per month were calculated and
entered into the study database. For this analysis, a single value for each patient data
point was used; the average of the monthly values was used regardless of time period on
hemodialysis modality. There were no duplicate observations for any patient.
Ethics
Because of concerns regarding the use of a standard dialysate of 140 mmol/L sodium
concentration and prompted by the observation of high IDWGs in patients undergoing
FNHD, a quality assurance investigation was instituted. All laboratory tests had been
taken as per routine care protocols; demographic and dialysis treatment information were
!
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available from patient records.

Once extracted, all data were de-identified before

analysis. No patient had to provide blood samples, answer questionnaires or do anything
specific for this study which was conducted in accordance with the Declaration of
Helsinki. Thus, informed written consent was not obtained from the current patients.
Statistics
Data were analyzed using the Statistical Package for Social Sciences (SPSS, IBM,
Armonk, New York, U.S.) version 19.0.
Patients exposed to different dialysis modalities were compared using two-tailed
student T-tests for continuous variables, and Fisher’s exact test for categorical variables.
Statistical significance was achieved with α<0.05.
The objective of this study was to determine if the sodium setpoint changed with
longer and more frequent exposure to the same dialysate sodium concentrations, when
patients transitioned from thrice weekly conventional hemodialysis to dialysis modalities
differing in duration and frequency (SHD, ICHD, INHD, FNHD). The “sodium setpoint”
was defined as the average pre-dialysis plasma sodium concentration over the time period
specified for each of three endpoints. The three endpoints were DeltaPRENA100,
DeltaPRENA100-150, and M100 (Figure 3.1). They are defined as follows:
DeltaPRENA100 is the difference between PRENA100+ and PRENA-50.
PRENA100+ is the average pre-dialysis plasma sodium concentration, after 100 days of
home hemodialysis, for the life of the patient while still on the same dialysis modality.
PRENA-50 is the average of all pre-dialysis plasma sodium values in the 50 days prior to
transition to home hemodialysis and while on ICHD.
Each patient’s period of time on home hemodialysis differed after the first 100
days. Thus, DeltaPRENA100-150 was also calculated as the difference between
PRENA100-150 and PRENA-50. The PRENA100-150 is the average pre-dialysis plasma
sodium concentration, between 100 and 150 days post-transition to home hemodialysis.
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Figure 3.1: Endpoints to Determine Existence of Sodium Setpoint
PRENA100+ and PRENA-50 were compared, as were PRENA100-150 and
PRENA-50 in each dialysis modality group, for all patients, and separately for patients
with PRENA-50 values a) greater than or equal to, or b) less than the dialysate sodium
concentration of 140 mmol/L. A statistically significant change between Pre and PostNa+ values implied a change in sodium setpoint.
A line of best fit was then calculated from the pre-dialysis plasma sodium values
versus time plot for each patient over the first 100 days after transitioning to home
hemodialysis. The slope of these lines of best fit was measured with its confidence
intervals (M100). The mean M100 values found in different dialysis modality groups
were compared overall, and again by PRENA-50/dialysate-Na+ relationship. A M100
with 95% confidence intervals that did not cross zero was evidence for a change in
sodium setpoint.
We chose the time period of 100 days because we wanted a minimum of 3 plasma
sodium measurements for each patient to calculate slope of pre-dialysis plasma sodium
concentration. Since each home hemodialysis patient undergoes monthly blood work,
most patients have a minimum of 3 pre-dialysis sodium concentrations within 100 days.
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Regression models were used to identify an association between the primary

outcome DeltaPRENA100 and a series of covariates. Specifically, univariate regression
analyses were performed using DeltaPRENA100, DeltaPRENA100-150, and M100 as
separately evaluated dependent variables. Independent variables evaluated included
dialysis frequency and duration, dialysate to (PRENA-50) difference (DPRENA-50), and
(DPRENA-50) times dialysis duration. We evaluated (DPRENA-50) times dialysis
duration, as an independent variable, since we have previously shown that this covariate
is predictive for interdialytic weight gain in a similar patient population.
Multivariate

regression

was

used

in

an

attempt

to

determine

how

DeltaPRENA100 was associated with dialysis frequency, duration, the dialysate to
PRENA-50 difference, and the dialysate to PRENA-50 difference times dialysis duration.
Here all patients were used regardless of dialysis modality.

Table 3.1: Demographic Factors of Dialysis Modality Groups

!

!
3.3

50!
Results

A total of 87 patients made up the database, with 31, 13, 30 and 13 from SHD, ICHD,
FNHD and INHD. There were 29, 13, 28 and 12 patients with sufficient data for
DeltaPRENA100 and DeltaPRENA100-150, and 31, 10, 26 and 11 patients with
sufficient data for M100 from SHD, ICHD, FNHD and INHD, respectively. A total of 29
patients had pre-transition pre-dialysis sodium setpoint greater than or equal to 140
mmol/L, with 12,3,12, 2 from SHD, ICHD, FNHD and INHD.
There were no statistically significant differences between dialysis modalities for
age, diabetes status, sex, or vintage of renal replacement prior to initiation of home
hemodialysis (Table 3.1). However, FNHD patients were heavier than ICHD patients
(87.5 versus 68.5 kg, p = 0.008). Residual renal function was higher in ICHD patients
than SHD patients (1.94 versus 0.27 mL/min/1.73 m2, p < 0.001). While on the assigned
dialysis modality, plasma albumin did not differ between groups. Pre-dialysis phosphate
concentration was lower in FNHD than SHD patients (1.56 versus 1.76 mmol/L, p =
0.044). Dialysis duration was shorter in SHD patients (142.3 min) than ICHD (202.3 min,
p <0.001), FNHD (408.6 min, p<0.001) and INHD patients (372.5 min, p<0.001), and
shorter in ICHD patients than FNHD (p<0.001) and INHD patients (p<0.001). Dialysis
frequency was greater in SHD patients (5.7 per week) than ICHD (3.1 per week,
p<0.001), FNHD (5.2 per week, p<0.001) and INHD patients (3.1 per week, p<0.001),
and greater in FNHD than ICHD (p<0.001) or INHD patients (p<0.001). Weekly dialysis
duration was lower in ICHD than SHD (633.7 vs. 803.4 minutes, p=0.001), lower in SHD
than INHD (803.4 vs. 1148.5 minutes, p<0.001) and lower in INHD than FNHD (1148.5
vs. 2128.1 minutes, p<0.001). Weekly ultrafiltration volume was lower in ICHD and
INHD than SHD (6.5 and 6.6 vs. 10.4 L, p<0.001 and p=0.004) and lower in ICHD and
INHD than FNHD (6.5 and 6.6 vs. 12.0 L, p<0.001 for both).
Sodium setpoint decreased in FNHD patients when all pre-dialysis sodium
concentrations from 100 days post-transition onwards were considered (PRENA-50 >
PRENA100+)(138.5 to 136.7 mM, p=0.015)(Figure 3.2).
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FNHD = frequent nocturnal hemodialysis; ICHD = intermittent conventional
hemodialysis; INHD = intermittent nocturnal hemodialysis; SHD = short hours daily
hemodialysis.
Figure 3.2: Pre-Dialysis Plasma Sodium Concentration Before (PRENA-50), Between
Days 100 to 150 After (PRENA100-150) and All Days from 100 days After
(PRENA100+) Transition to Home Hemodialysis
In both SHD and FNHD patients whose pre-transition pre-dialysis sodium
(PRENA-50) was greater than or equal to the dialysate sodium of 140 mM, sodium
setpoint decreased when post-transition pre-dialysis sodium concentrations from 100
days onwards were considered (PRENA-50 > PRENA100+) (SHD 140.2 to 138.7 mM,
p=0.019; FNHD 140.5 to 137.1 mM, p=0.001) (Figure 3.3). When pre-dialysis plasma
sodiums were restricted to post-transition days 100 to 150, the sodium setpoint still
decreased in both SHD and FNHD patients (SHD 140.2 to 138.6 mM, p=0.030; FNHD
140.5 to 138.0 mM, p=0.008) (Figure 3.3).
There was no difference in any dialysis modality group, between PRENA-50 and
PRENA100+, or between PRENA-50 and PRENA100-150, if the pre-transition pre-
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dialysis sodium (PRENA-50) was less than the dialysate sodium concentration of 140
mM (Figure 3.4).

FNHD = frequent nocturnal hemodialysis; ICHD = intermittent conventional
hemodialysis; INHD = intermittent nocturnal hemodialysis; SHD = short hours daily
hemodialysis.
Figure 3.3: Pre-Dialysis Plasma Sodium Concentration Before (PRENA-50), Between
Days 100 to 150 After (PRENA100-150) and All Days From 100 Days After
(PRENA100+) Transition to Home Hemodialysis, with Pre-Transition
Setpoint > 140 mmol/L
The slope of pre-dialysis plasma sodium in the first 100 days post-transition
(M100) was less than zero in all SHD (95% CI, -0.0055 to -0.0318 mM/day) and FNHD
(95% CI, -0.0010 to -0.0394 mM/day) patients, and in SHD (95% CI, -0.0081 to -0.0351
mM/day) and FNHD (95% CI, -0.0209 to -0.0695 mM/day) patients whose pre-transition
pre-dialysis sodium (PRENA-50) was greater than or equal to 140 mM (Figure 3.5).
Univariate regression analysis was performed to predict M100 using 73 data-sets
from 29 SHD, 9 ICHD, 24 FNHD and 11 INHD patients. Univariate correlation
coefficients and p values are shown (Table 3.2). The strongest predictor of M100 was the
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dialysate to pre-dialysis plasma sodium difference (DPRENA-50)(R2 = 12.65%) although
no independent factor reached statistical significance (Table 3.1).

FNHD = frequent nocturnal hemodialysis; ICHD = intermittent conventional
hemodialysis; INHD = intermittent nocturnal hemodialysis; SHD = short hours daily
hemodialysis.
Figure 3.4: Pre-Dialysis Plasma Sodium Concentration Before (PRENA-50), Between
Days 100 to 150 After (PRENA100-150) and All Days From 100 Days After
(PRENA100+) Transition to Home Hemodialysis, With Pre-Transition
Setpoint < 140 mmol/L
Univariate regression analysis was performed to predict DeltaPRENA100 and
DeltaPRENA100-150 using 82 data-sets from 29 SHD, 13 ICHD, 28 FNHD and 12
INHD patients. Univariate correlation coefficients and p values are shown (Table 3.2).
The covariate of (DPRENA-50)(dialysis time) had a correlation of 31.8% and 42.0% for
DeltaPRENA100 and DeltaPRENA100-150, respectively. However, this was entirely due
to the DPRENA-50 component; elimination of dialysis duration from the covariate
improved the correlation coefficient and p value in both DeltaPRENA100 (R2 = 31.8 to
32.8%, p = 0.540 to 0.030) and DeltaPRENA100-150 (R2 = 42.0 to 42.0%, p = 0.859 to
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0.002). Dialysis frequency (R2 = 6.19%, p = 0.060) and dialysis duration (R2 = 2.15%, p
= 0.085) trended towards a relationship with DeltaPRENA100.
A multivariate model was created to investigate the association of
DeltaPRENA100 with dialysis frequency and DPRENA-50.
Model 1
DeltaPRENA100

=

0.4765 (DPRENA-50)
- 0.3506 (dialysis frequency per week) – 0.2807

R2

=

35.44% (adjusted R2 = 33.8%)

F-statistic

=

21.68 (on 2 and 79 degrees of freedom, p<0.001)

DeltaPRENA100

=

(Post100-Na+) – (PRENA-50)

DPRENA-50

=

(Dialysis Na+) – (PRENA-50),
adjusted p value < 0.001, R2 = 32.8% in univariate model

Dialysis frequency

=

Dialysis sessions per week,
adjusted p value = 0.077, R2 = 6.2% in univariate model

Table 3.2: Univariate Regression Coefficients and P values for Independent Variables
Predicting Slope of Predialysis Na+ in first 100 days (M100), Difference in
Pre and Post-100 Days Post-Transition Pre-Dialysis Na+ (DeltaPRENA100+)
and Differences in Pre- and Days 100-150 Post-Transition Pre-Dialysis Na+
(DeltaPRENA100-150)
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Discussion

The sodium setpoint is considered to be stable in hemodialysis patients. The results of
this study suggest that this is true at least with ICHD. According to model 1, this
assumption is reasonable in ICHD patients; a pre-dialysis sodium between 133.0 and
141.0 mmol/L would be associated with DeltaPRENA100 between -2 and 2 mmol/L.
This difference could be attributed to changes in total body water, or to laboratory
measurement variability. In Keen and Gotch’s initial description of the stability of the
pre-dialysis sodium setpoint,3 89% of patients had an average pre-dialysis plasma sodium
from 133.0 mM to 141.0 mM.

FNHD = frequent nocturnal hemodialysis; ICHD = intermittent conventional
hemodialysis; INHD = intermittent nocturnal hemodialysis; SHD = short hours daily
hemodialysis.
Figure 3.5: Slope of Pre-Dialysis Plasma Sodium Concentration, in First 100 Days After
Transition from Conventional Thrice Weekly (ICHD) to Home Hemodialysis
for All patients, and for Patients with Initial Sodium Setpoint (SP) > or < 140
mmol/L
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However, there are scenarios in which a sodium setpoint change may occur on the

basis of model 1. Patients whose dialysate sodium is personalized to be equal or less than
pre-dialysis sodium may decrease their sodium setpoint. For example, in a patient
dialyzed 5 times weekly, with a pre-dialysis plasma sodium of 135 mmol/L, whose
dialysate sodium is personalized to 132 mmol/L, in an attempt to “desalt,” the associated
DeltaPRENA100 would be -3.5 mmol/L (model 1), which would bring the pre-dialysis
plasma sodium setpoint down to 131.5 mmol/L, a level associated with increased
mortality.16,17
Furthermore, patients dialyzed in units using a “standard dialysate sodium
concentration” may increase their pre-dialysis plasma sodium setpoint. For example, a
patient dialysed 3 times weekly, with a setpoint of 130 mmol/L, whose dialysate sodium
is 140 mmol/L would have an associated DeltaPRENA100 of +3.4 mmol/L (model 1),
setting the new pre-dialysis plasma sodium setpoint to 133.4 mmol/L. These patients
would not have been observed in the Keen and Gotch’s description, since none of their
patients had sodium setpoints under 131 mmol/L. It is unknown whether the increased
interdialytic weight gain observed in patients with a large dialysate to pre-dialysis plasma
sodium difference, is offset by any improvement in mortality by increasing the sodium
setpoint. If so, this may in part explain the unexpected results of Hecking et al, 15,19 who
discovered that patients whose pre-dialysis sodium was less than 137 mmol/L had
improved mortality when dialyzing against a higher dialysate sodium concentration, and
reduced hospitalization and mortality with higher dialysate sodium concentrations, in
units that did not individualize dialysate sodium concentrations. Dialysate sodium
prescriptions may have changed some of the pre-dialysis sodium concentrations from a
low level to a level associated with improved mortality. Prospective trials should evaluate
the effect of intentionally increasing pre-dialysis plasma sodium setpoints, on
cardiovascular and all-cause mortality.
Determining the pathophysiology of a change of plasma sodium setpoint is not the
objective of this study, and will need to be established prospectively. Stability in blood
glucose, lipid and paraprotein concentrations needs to be initially assumed. Then if a
patient has a pre-dialysis plasma sodium concentration greater than the dialysate sodium
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concentration, one could hypothesize that the post-dialysis plasma sodium concentration
would decrease towards the dialysate sodium concentration, since sodium loss would
occur relative to the isosmotic ultrafiltration, leaving the plasma with relative sodium to
water loss. It is possible that equilibration back to sodium setpoint homeostasis requires
an interdialytic interval longer than patients on quotidian, but not intermittent
hemodialysis modalities. This hypothesis would need to be evaluated prospectively.
However, this would explain why adding (dialysis time) to (DPRENA-50) did not
improve (DPRENA-50) prediction of DeltaPRENA100 (Table 3.2), since dialysis
frequency is a much greater determinant of interdialytic interval duration. For example,
doubling a patient’s dialysis duration from 4 to 8 hours (at dialysis frequency 3 times a
week) only marginally decreases interdialytic time interval from 39.0 to 36.0 hours,
whereas doubling a patient’s dialysis frequency from 3 to 6 weekly sessions (at dialysis
duration 4 hours a session) significantly decreases interdialytic time interval from 39.0 to
20.6 hours. Indeed, a patient with a pre-dialysis plasma sodium setpoint of 140 mmol/L,
dialyzing 7 days weekly with a dialysate sodium of 140 mmol/L, would decrease their
pre-dialysis plasma sodium setpoint to 137 mmol/L; this is a surprising and unexpected
finding, the etiology of which will need to be elucidated with prospective investigations.
Finally, quotidian dialysis therapies appear from these results to be associated
with an increased chance of decreasing the sodium setpoint when the initial pre-dialysis
plasma sodium setpoint is equal to or greater than the dialysate sodium (Figure 3.3). For
example a patient on 6 nights a week hemodialysis, with an initial pre-dialysis plasma
sodium of 143 mmol/L, and a dialysate sodium concentration of 140 mmol/L will have a
DeltaPRENA100 of -3.8, bringing the pre-dialysis plasma sodium setpoint to 140.2
mmol/L. Targeting the dialysate sodium concentration to below the pre-dialysis sodium
setpoint could lead to repeated drops in the pre-dialysis sodium with every change in
dialysate concentration. This may be undesirable from an outcome perspective.
Any statistically significant changes in pre-dialysis plasma sodium setpoint were
observed with 150 days after transition from thrice weekly conventional to home
hemodialysis (Figure 3.3). It is thus unlikely that any decreases in pre-dialysis sodium
setpoint related to patients developing comorbidities associated with lower plasma
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sodium concentrations such as heart or liver disease. Indeed, the strongest associations
with change in plasma sodium setpoint were iatrogenic, specifically the choices of
dialysis frequency and the dialysate sodium to pre-dialysis plasma sodium difference
(Table 3.2). Furthermore, only outpatient blood tests were considered, so acute illness or
comorbid illness is unlikely to be a confounding factor.
In light of numerous studies that suggest personalizing dialysate sodium
concentrations can decrease interdialytic weight gain,6-13 these data give reason for
caution. If dialysate sodium is intentionally decreased to the pre-dialysis plasma sodium
concentration, the IDWG may fall, but any benefit in morbidity and mortality may be
offset by a decrease in sodium setpoint.
There are weaknesses to this study. Firstly, all data in this study were
retrospective and measurements did not occur at exact time intervals in all patients. Thus,
it remains unclear whether any change in sodium setpoint is a continuous process, or if
any change is upon initiation of dialysis and complete after a short interval of time.
However, the pre-dialysis plasma sodium setpoint change was completed within 150 days
in our study, suggesting that patients reach a new “steady state” in which the effects of
dialysis frequency and dialysate to pre-dialysis plasma sodium difference offset each
other. Secondly, data points used were aggregates of variable numbers of dialysis and
laboratory values occurring between variable time periods. This may explain why model
1 only provides 35% explanation for the change in DeltaPRENA100. Thirdly, there were
baseline differences between dialysis modality groups, such as residual renal function and
patient weight, which may be confounders. The study also has strengths in that numerous
pre-dialysis plasma sodium values are available and that modalities differing in frequency
and duration were used with this home hemodialysis population. While the sample size of
patients was small (n=87), the findings were statistically significant and likely of clinical
importance.
Further studies are indicated in quotidian hemodialysis patients that will vary
prospectively the dialysate sodium to establish the effect of dialysate sodium and sodium
setpoint on cardiovascular morbidity and all cause mortality.
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Conclusions

In hemodialysis patients, the pre-dialysis plasma sodium “setpoint” is dynamic and
correlated to the dialysate sodium concentration and dialysis frequency. Nephrologists
should consider how the selected dialysate sodium concentration affects the dialysate to
pre-dialysis plasma sodium concentration difference, and should also continue to monitor
pre-dialysis plasma sodium concentrations. Prospective trials are needed to establish
when the benefits of a decrease in interdialytic weight gain are offset by a decrease in
sodium setpoint, and how dialysate sodium concentration should be targeted to minimize
cardiovascular and all-cause mortality.
3.6
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Introduction

The amount of sodium removed from a patient on hemodialysis is the sum of convective
loss and the diffusive gain or loss on dialysis.1 Diffusive sodium balance on thrice weekly
intermittent conventional hemodialysis (ICHD) is associated with important clinical
outcomes, including interdialytic weight gain (IDWG), blood pressure, intradialytic
hypotension, cardiovascular morbidity and mortality.2-6 Which aspect of sodium balance
is best to follow (and perhaps influence) is controversial; while decreasing dialysate
sodium decreases thirst, IDWG and blood pressure,1-8post-dialysis minus pre-dialysis
plasma sodium (PPNa+) may be superior to dialysate sodium minus pre-dialysis plasma
sodium (DPNa+) in predicting mortality.6
While the effects of PPNa+ and DPNa+ in ICHD have been reported, those in
more frequent dialysis modalities remain unknown. The objective of this study was to
determine whether DPNa+ or PPNa+ better predicted clinical outcomes in patients on
short hours daily (SHD) and frequent nocturnal home hemodialysis (FNHD) and to
define these outcomes in FNHD and SHD.
4.2

Materials and Methods

All patients who received treatment through the Southwestern Ontario Regional Home
Hemodialysis program base in London Ontario, from 1985 to December 31, 2011 were
considered (n=101). A retrospective observational study was used. Patients were required
to be on an assigned dialysis modality for a minimum of 120 days, to facilitate adequate
record collection (n=92). All patients included in this trial initiated home hemodialysis
after January 1, 1998. Patients who were on either short hours daily (SHD) (n=35) or
frequent

nocturnal

hemodialysis

(FNHD)

(n=38)

were

included.

Intermittent

conventional hemodialysis (ICHD) (n=11) and intermittent nocturnal hemodialysis
(INHD) (n=8) patients were excluded because of their low numbers.
Dialysis Modality and Characteristics
SHD home (n=35) was defined as a minimum of 5 treatments per week, with a minimum
treatment time of 1.5 hours and a maximum treatment time of 4.0 hours. FNHD home
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(n=38) was defined as a minimum of 5 treatments per week, with a minimum treatment
time of 6.0 hours.
Dialysate sodium concentration was 140 mmol/L for all patients. Dialysate
bicarbonate and potassium concentrations were personalized for each patient, to
normalize pre-dialysis potassium and bicarbonate concentrations. Dialysate calcium
concentration was 1.25 mEq/L for all SHD patients. From December, 2001 onwards, all
FNHD patients dialyzed using a 1.75 mEq/L Ca++ dialysate concentration, as is now
considered standard practice.9 Prior to December, 2001, patients’ dialysate calcium
concentration was either 1.25 or 1.75 mEq/L. Thus, the majority of FNHD patients
(26/38, 68.4%) used a dialysate calcium concentration of 1.75 mEq/L for the entire
duration of this trial, and for those patients who initiated home hemodialysis prior to
December 2001, 40.6% of data were collected while dialysate calcium concentration was
1.75 mEq/L.
Blood sample collection
Pre and post-dialysis blood samples are routinely taken each month. Home patients are
trained to take blood from the arterial blood line at the start of dialysis and post-dialysis,
using a standard slow blood and stop dialysate method. The samples are centrifuged and
then stored and refrigerated until delivered to the local laboratory for that patient. All
patient blood tests are measured using automated and standardized methods. Of interest
to this study were pre-dialysis plasma sodium, bicarbonate and albumin, and post-dialysis
plasma sodium values.
Sodium concentration measurement
Plasma sodium concentration was measured using Beckman-Coulter LX20 Pro
Chemistry Analyzer with Ion Selective Electrodes prior to, and Roche Modular P
Chemistry Analyzer with Ion Selective Electrodes after November 4, 2008.
Dialysate sodium concentration was determined using online conductivity
measurements built into the Fresenius H series hemodialysis machine, which was used
for all patients.
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Database Creation
Blood test results were obtained from the hospital electronic patient record (PowerChart
by Cerner). Data from individual patients were only used in the study if a minimum of 3
pre- and post-dialysis plasma sodium sets were available.
IDWG, pre and post-dialysis systolic and diastolic blood pressures, dialysis
treatment times, and ultrafiltration volumes were obtained from archived dialysis
treatment run sheets. These were the defined outcomes. The average values for these per
month were calculated and entered into the study database. Summary measures were used
at the patient level to avoid issues of correlation within patients. As such, a single value
representing the average monthly value for each outcome per person was used in the
analyses regardless of patient hemodialysis vintage.
Demographic patient information, including age, sex, weight (kg) at initiation of
therapy, presence of diabetes, months of renal replacement therapy prior to initiation of
home hemodialysis, and date of initiation of home hemodialysis were recorded by chart
review. The blood pressure before initiation of home hemodialysis was recorded from the
pre-home hemodialysis assessment clinic, which is within 1 month of initiation.
Residual glomerular filtration rate at initiation of home hemodialysis (Kr in
mL/min/1.73m2), was calculated using 24 hour urine collections for urinary urea and
creatinine, as previously described.10 Residual urinary volume was not commonly
recorded, and thus residual renal function was used instead. Patients who urinated less
than 250 mL urine daily were recorded to have no residual renal function.
Ethics
Because of concerns regarding the use of a standard dialysate of 140 mmol/L sodium
concentration and prompted by the observation of high IDWGs in patients undergoing
FNHD, a quality assurance investigation was instituted. All laboratory tests had been
taken as per routine care protocols; demographic and dialysis treatment information were
available from patient records.

Once extracted, all data were de-identified before

analysis. No patient had to provide blood samples, answer questionnaires or do anything
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specific for this study that was conducted in accordance with the Declaration of Helsinki.
Thus, informed written consent was not obtained from the current patients.
Statistics
Data were analyzed using the Statistical Package for Social Sciences (SPSS) version
19.0. The average for all demographic factors was calculated. To compare FNHD and
SHD patients at baseline, p-values were calculated using two tailed student t-test for
continuous variables and Fisher’s exact test for categorical variables. Each baseline
demographic and clinical factor’s distribution was assessed. When a non-normal
distribution was found, that factor’s median and interquartile ranges were calculated.
To evaluate which of DPNA or PPNA better predicted the clinical endpoints,
univariable analyses using dependent variables of IDWG, pre-dialytic systolic and
diastolic blood pressures, intradialytic change in systolic and diastolic blood pressures,
and ultrafiltration rate were conducted SHD and FNHD patients were considered
collectively, then separately. R2 and p-values were calculated, and a p-value of less than
or equal to 0.05 was considered statistically significant.

DPNa+ = dialysate minus pre-dialysis plasma sodium concentration; PPNa+ = Postminus Pre-dialysis plasma sodium concentration.
Table 4.1: Number of Observations for Pre- to Post Hemodialysis (PPNa+) and Dialysate
to Pre-Hemodialysis (DPNa+) Sodium Gradient, and for Each Clinical
Outcome
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The mean, median, range, interquartile ranges and variance in the number of

observations for DPNa+ and PPNa+, and for each clinical outcome, were calculated. The
effects of DPNa+ and PPNa+ on IDWG, pre-dialytic systolic and diastolic blood
pressures, intradialytic change in systolic and diastolic blood pressures, and ultrafiltration
rate were compared between SHD and FNHD using two tailed student t-tests. Statistical
significance was considered at p ≤ 0.05.
4.3

Results

A total of 73 sets of time-averaged pre- and post-dialysis plasma sodium values were
made from 2065 matched pre- and post-dialysis plasma sodium values. There were a
mean and median number of 28.3 and 16.0 observations for each patient’s PPNa+ and
41.1 and 27.0 observations for each patient’s DPNa+ (Table 4.1). The majority of all
patients combined (90.4%), and each of SHD (88.6%) and FNHD (92.1%) had predialysate plasma sodium values less than the dialysate sodium of 140 mmol/L(Figure
4.1). The majority of all patients combined (96.5%) and each of SHD (97.1%) and FNHD
(94.7%) had post-dialysis plasma sodium levels less than the dialysate sodium of 140
mmol/L (Figure 4.2).
There were a mean and median of 13.1 and 8.0 observations for each patient’s
IDWG, 12.9 and 8.0 observations for each patient’s paired pre and post hemodialysis BP,
and 13.5 and 8.0 observations for each patient’s ultrafiltration volume (Table 4.1).
All background demographic and clinical factors had a normal distribution (Table
4.2), except for residual renal function (mL/min) and vintage of renal replacement prior
to initiation of home hemodialysis (months). The mean, median and first to third
interquartile ranges for dialysis vintage (months) were 67.0, 50.0 and 18.0 to 102.0 for
SHD and 94.5, 71.0, and 24.0 to 121.0 for FNHD. The mean, median and first to third
interquartile ranges for residual renal function (mL/min) were 0.47, 0.00 and 0.00 to 0.00
for SHD and 0.78, 0.00, and 0.00 to 0.84 for FNHD.
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FNHD = frequent nocturnal hemodialysis; SHD = short hours daily hemodialysis
Figure 4.1 Pre-Dialysis Plasma
Figure 4.2: Post-Dialysis Plasma
Sodium Concentration
Sodium Concentration

SHD patients had a slightly higher dialysis frequency (Table 4.2) (5.54 vs. 5.26
sessions per week, p=0.03), and as expected, a lower dialysis duration (146.0 vs. 402.8
minutes, p<0.001) than FNHD patients.
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Table 4.2: Demographic and Clinical Factors of Patients on Short Hours Daily and
Frequent Nocturnal Home Hemodialysis
PPNa+ was superior to DPNa+ in predicting IDWG (Table 4.3) in SHD patients
(R2 = 0.105 vs. 0.019, p=0.04 vs. 0.68), FNHD patients (R2 = 0.223 vs. 0.020, p=0.002
vs. 0.76) and combined (R2 = 0.147 vs. 0.024, p=0.001 vs. 0.75). PPNa+ was superior to
DPNa+ in predicting pre-dialysis systolic blood pressure in SHD patients (R2 = 0.103 vs.
0.007, p = 0.02 vs. 0.82). PPNa+ was superior to DPNa+ in predicting intradialytic
change in systolic BP in FNHD patients (R2 = 0.100 vs. 0.002, p=0.02 vs. 0.16) and
combined patients (R2 = 0.042 vs. 0.015, p = 0.002 vs. 0.02). PPNa+ was superior to
DPNa+ in predicting intradialytic change in diastolic BP in FNHD patients (R2 = 0.066
vs. 0.019, p = 0.02 vs. 0.06) and combined patients (R2 = 0.014 vs. 0.060, p=0.004 vs.
1.0). PPNa+ was superior to DPNa+ in predicting ultrafiltration rate in FNHD patients
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DPNa+ = Dialysate minus Pre-dialysis plasma sodium concentration; FNHD = frequent
nocturnal hemodialysis; PPNa+ = Post- minus Pre-dialysis plasma sodium concentration;
SHD = short hours daily hemodialysis
Table 4.3: PPNa+ and DPNa+ Versus Clinical Outcomes in Short Hours Daily and
Frequent Nocturnal Hemodialysis
(R2 = 0.296 vs. 0.036, p = 0.001 vs. 0.52) and combined patients (R2 = 0.038 vs. 0.003, p
= 0.05 vs. 0.73).
DPNa+ was superior to PPNa+ in predicting intradialytic change in diastolic BP
in SHD patients (R2 = 0.101 vs. 0.003, p=0.02 vs. 0.13). No other statistically significant
differences were found between DPNa+ and PPNa+, for any clinical endpoints.
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Ultrafiltration rate was significantly lower in FNHD than SHD patients (0.035 vs.

0.77 L/hour, p < 0.001) (Table 4.4). While IDWG appeared higher in FNHD than in SHD
patients (2.25 vs. 1.92 L), this approached but did not reach statistical significance
(p=0.06). There were no other statistically significant differences in clinical outcomes
between SHD and FNHD patients.

Table 4.4: Clinical Endpoints of Standardized Dialysate Bath of 140 mmol/L in Short
Hours Daily Versus Frequent Nocturnal Hemodialysis Patients
PPNa+ correlated with increased interdialytic weight gain in both SHD and
FNHD patients, but this correlation was stronger in FNHD patients (R2 = 0.105 vs.
0.019), with greater statistical significance (p = 0.04 vs. 0.68) and with greater slope
(0.166 vs. 0.134) (Figure 4.3).
In FNHD patients, PPNa+ associated with greater drops in systolic (slope= 1.847, R2 = 0.100, p = 0.02) and diastolic (slope = -0.866, R2 = 0.066, p = 0.02) blood
pressures on dialysis (Figure 4.4). This was in contrast to SHD patients, in whom a
greater DPNa+ associated with a decreased drop of diastolic blood pressure (slope
=0.786, R2 = 0.101, p=0.02) (Table 4.3). This is shown graphically (Figure 4.4); as postdialysis plasma sodium increases relative to pre-dialysis plasma sodium in FNHD
patients, there is more of a drop in systolic and diastolic blood pressures on dialysis. On
the other hand, as dialysate sodium increases relative to pre-dialysis plasma sodium in
SHD patients, the magnitude of diastolic blood pressure fall on dialysis decreases.
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Figure 4.3: Effect of PPNa+ on Interdialytic Weight Gain for Short Hours Daily and
Frequent Nocturnal Hemodialysis Patients
4.4

Discussion

Total sodium balance on hemodialysis is determined by the net of convective loss and
diffusive sodium gain or loss.1 Positive sodium balance in patients on thrice weekly
conventional hemodialysis is associated with IDWG, and, in turn hypertension, left
ventricular hypertrophy and cardiovascular morbidity and mortality.1,5-8,13 Both low and
high pre-dialysis systolic blood pressures are associated with increased mortality in
patients undergoing thrice weekly hemodialysis. However, the clinical effects of more
frequent and longer duration exposure to a dialysate higher than the pre-dialysis plasma
sodium has not been described.
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Figure 4.4: Intradialytic Change in Blood Pressure in Short Hours Daily and Frequent
Nocturnal Hemodialysis Patients
Understanding which of DPNa+ or PPNa+ better predicts clinical outcomes is
important not only in determining which factors are modifiable, but also to design
prospective trials aimed at improving outcomes. Reducing dialysate sodium has been
shown to improve IDWG and blood pressure,1,3-7and DPNa+ has been correlated to
IDWG.16 However, in large population observational data, PPNa+ appears superior to
DPNa+ in predicting IDWG in ICHD.17 Our study confirms that in quotidian dialyzed
patients, PPNa+ has a stronger association than DPNa+ with IDWG, intradialytic change
in blood pressure, and ultrafiltration rates, consistent with recent work of Hecking et al.17
IDWG was more strongly correlated to PPNa+ in FNHD than SHD patients (R2=0.223
vs. 0.105), and with greater statistical significance (p=0.002 vs. 0.04) and slope (0.166 vs.
0.134) (Table 4.3) (Figure 4.3). This reflects the longer exposure to a positive diffusive
difference (402.8 vs. 146.0 minutes, p < 0.001) (Table 4.2). This is consistent with the
recent work of Munoz-Mendoza et al, who showed decreased IDWG and blood pressure
in thrice weekly nocturnal patients exposed to lower dialysate sodium concentrations.18
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DPNa+ was more correlated than PPNa+ with intradialytic change in blood

pressure, in SHD patients. This was the only clinical variable associated more with
DPNa+ than PPNa+. This was in contrast to FNHD patients, where PPNa+ was more
associated with change in BP on dialysis, only in the opposite direction (Figure 4.4). This
may result from a variety of factors. Firstly, FNHD patients are exposed to a diffusive
difference longer and thus have a more positive sodium balance. While the higher IDWG
in FNHD patients in our trial did not reach statistical significance (2.25 vs. 1.92 L,
p=0.06)(Table 4.4), patients in the London Daily Nocturnal Dialysis Study with a
dialysate sodium of 140 mM had higher IDWG in FNHD vs. SHD patients. This may
cause the intradialytic change in blood pressure to reflect relative ultrafiltration
requirements, which are higher with more positive sodium balance (Table 4.3). Secondly,
it’s possible that the recumbent position of FNHD patients has different effects on the
effective circulating volume (ECV), and that time upright is needed before this
approximates the ECV of SHD patient undergoing ultrafiltration of a similar volume.
Finally, FNHD patients may have greater restoration in homeostasis of hormones
involved in blood pressure regulation. The generation of intradialytic hypotension is
associated with autonomic neuropathy17which may be improved by nocturnal dialysis
modalities.20
Intradialytic hypotension is associated with increased mortality in patients
undergoing thrice weekly hemodialysis.20 However, the increased intradialytic drop in
blood pressure in FNHD patients with an increased PPNa+ is of uncertain clinical
significance. FNHD patients are on less anti-hypertensive medications than SHD patients,
and suffer from fewer dialysis related symptoms like cramping, headaches, dizziness,
dyspnea, and self-reported intradialytic hypotension.22 The study provides clinically
important information. Firstly, the majority of quotidian patients (90.4%) are exposed to
a positive diffusive difference for sodium (Figure 4.1). Ideally, this dialysate sodium
should be targeted to minimize IDWG, to improve blood pressure and to minimize risk of
intradialytic hypotension. This can be achieved by personalizing the dialysate sodium so
that PPNa+ is zero or even slightly negative. This effect appears more crucial in FNHD
than SHD patients, because of the longer duration of therapy. Furthermore, a negative
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DPNa+ or PPNa+ does not seem to predispose FNHD patients to the risk of intradialytic
hypotension as it does in SHD patients.
This study does have limitations. A relatively small number of patients of variable
dialysis vintage were studied in a retrospective fashion. All data points were aggregates
of variable numbers of dialysis and laboratory values, occurring between variable time
periods, corresponding to patients’ attendance at clinics, when data were entered into the
electronic patient record. However, numerous pre- and post-dialysis sodium values were
available from two quotidian dialysis modalities. The active plasma sodium available for
diffusion could not be quantified precisely in this study. However, the concentration of
major plasma anions albumin and bicarbonate were not statistically different pre-dialysis
(Table 4.2), suggesting that the Gibbs-Donnan effect23 did not operate disproportionately
in one dialysis modality.
In conclusion, the PPNa+ has a greater association than DPNa+ to IDWG, predialysis systolic blood pressure, intradialytic blood pressure change and ultrafiltration
rates in SHD and FNHD patients. However, DPNa is associated with intradialytic
diastolic blood pressure change in SHD, but not in FNHD patients. In the latter, a
positive sodium balance increases the risk of large blood pressure drops on dialysis.
Further work is needed to establish the effect of altering dialysate sodium concentration,
on long-term cardiovascular outcomes, in quotidian dialyzed patients.
4.5
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Chapter 5: Modifiable Variables Affecting Interdialytic Weight Gain Include
Dialysis Time, Frequency, and Dialysate Sodium.
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Introduction

Intradialytic sodium (Na+) removal leads to decreased blood pressure1-3 and decreased
interdialytic weight gain (IDWG).4-8 This may lead to better outcomes9 in hemodialysis
patients, although this is controversial.12 The amount of Na+ removed from a patient
during hemodialysis is the net of that lost by convection with that lost or gained by
diffusion.4 Diffusive gain occurs when the dialysate Na+ exceeds the pre-dialysis plasma
Na+. In the London Daily Nocturnal Dialysis study,10 IDWG was higher in frequent
nocturnal (FNHD) than short hours daily hemodialysis (SHD) patients, using a standard
dialysate concentration of 140 mmol/L, suggesting that the time of exposure to a higher
dialysate Na+ may affect IDWG. In contrast, the Frequent Hemodialysis Network
(FHN)11 showed less IDWG in FNHD patients but they had variable dialysate Na+
concentrations and higher urinary volumes. Thus, factors that determine IDWG may
include residual urinary volume, dialysis time and frequency, and the dialysate to plasma
diffusion difference (DPNa+). A recent study determined that pre to post dialysis change
in plasma Na+ (PPNa+) better correlated to clinical outcomes than did the δDPNa+.8
However, the effect of DPNa+ on mortality remains controversial, with one large
prospective cohort study showing positive DPNa+ associated with decreased mortality,12
contrary to the findings of previous studies.13 However, PPNa+ is likely the result of both
DPNa+ and time of exposure to the diffusive Na+ difference.
The study objective was to derive an equation, using multivariable regression
analysis, of modifiable variables that affect IDWG.
5.2

Materials and Methods

Study Population
All patients in the home hemodialysis program of the Southwestern Ontario Regional
Renal Program, from February 11, 1998 to December 1, 2012, were included, using a
retrospective observational design.
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Dialysis Modality
Modality was defined by the duration of dialysis and its frequency. SHD implied a
minimum of 5 weekly treatments with treatment times of 1.5-4.0 hours. Intermittent
conventional hemodialysis (ICHD) meant a maximum of 4 weekly treatments and times
between 3-5 hours. FNHD indicated a minimum of 5 weekly treatments of 6.0 hours or
more. Dialysate Na+ concentration was always 140 mmol/L. When patients changed
dialysis modality during the observation period, only the first dialysis modality was
considered.
Blood sample collection
Pre and post dialysis blood samples are taken each month from the arterial blood line
using a standard slow blood and stop dialysate method. Locking solution (3 mL 4%
citrate) and a small amount of blood (2 mL) are always spent before blood is collected.
The samples are centrifuged, stored and refrigerated until delivered to the laboratory. Of
interest to this study were pre and post-dialysis plasma Na+ and pre-dialysis albumins,
measured using automated and standardized methods. Only outpatient blood tests were
used, to assure that the patient was at their baseline health status, so that the plasma Na+
concentration would not be confounded by acute illness.
Na+ concentration measurement
Plasma Na+ concentration was measured using Beckman-Coulter LX20 Pro Chemistry
Analyzer with Ion Selective Electrodes prior to, and Roche Modular P Chemistry
Analyzer with Ion Selective Electrodes after November 4, 2008. This change was made
by the London Health Sciences Center because of a need for higher volume of laboratory
testing. Both plasma Na+ concentration methods were regularly calibrated; thus, the
measurements were treated as equivalent on data analysis. Dialysate Na+ concentration
was determined using online conductivity measurements built into the Fresenius H series
hemodialysis machine, which was used for all patients. Blood glucose was not measured
simultaneous to Na+ concentration; thus, plasma sodium levels were not corrected for
glucose.
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Database Creation
Blood test results were available from the hospital electronic patient record (Power Chart
by Cerner). IDWG and dialysis treatment times were obtained from dialysis treatment run
sheets. The average monthly values were calculated and entered into the database. For
this analysis, a single value for each patient data point was used, being the average of the
monthly values regardless of hemodialysis vintage. Demographic patient information,
including age, sex, weight (kg) and height (cm) at initiation of therapy, diabetic status,
and months of renal replacement therapy prior to initiation of home hemodialysis, were
recorded by chart review. Residual glomerular filtration rate (ml/min x 1.73 m2) at
baseline14 was recorded. Our home hemodialysis program does not perform urine
collections if the 24 hour urine volume is less than 250 mL, since we have found that this
amount only marginally contributes to weekly standard Kt/V. Thus, patients with less
than 250 mL urine daily were recorded as having zero renal function. Once obtained, data
was de-identified and then entered into the study specific database for analysis.
Interdialytic Weight Gain
IDWG was calculated as the difference between the post-dialysis body weight and the
next dialysis session’s pre-dialysis body weight. A single IDWG value for each patient
was entered into the database, being the average of the monthly values regardless of
hemodialysis vintage.
We chose to use interdialytic weight gain as an absolute value (IDWG), rather
than as a percentage of body weight (IDWG%BW), for three reasons. Firstly, using all
available clinical and demographic variables, the unadjusted correlation coefficient was
higher for IDWG than IDWG%BW (R2 = 37.3% vs 32.2%). Secondly, on home
hemodialysis run sheets, patients did not always record body weight simultaneous to
IDWG, so there was temporal inaccuracy in IDWG%BW measurements. Thirdly,
IDWG%BW was autocorrelated with age, diabetes status and PPNa+, each of which were
important to assess in our final model.
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Ethics
Because of concerns regarding the use of a standard dialysate of 140 mmol/L Na+
concentration and prompted by the observation of high IDWGs in patients undergoing
FNHD, a quality assurance investigation was instituted. All laboratory tests had been
taken as per routine care protocols; demographic and dialysis treatment information were
available from patient records. Once extracted, all data was de-identified before analysis.
No patient had to provide blood samples, answer questionnaires or do anything specific
for this study which was conducted in accordance with the Declaration of Helsinki.
Thus, informed written consent was not obtained from the current patients.
Statistics
Two time periods were considered. Data prior to December 30, 2011 were used to
determine the equation for IDWG, which was internally validated using bootstrapping.
External validation used data from a temporally distinct population group, from August 1
to December 10, 2012.
Univariate analyses were used to investigate the relationship of each covariate
with the dependent variables. Descriptive statistics and univariable analyses were
conducted using the Statistical Package for Social Sciences (SPSS) version 19.0.
Multivariable regression models were used to develop predictive models through
backwards selection and a comparison of the adjusted Akaike Information Criterion
(AIC) of nested models.15 Starting with a saturated model (containing all potential
covariates) each independent variable starting with the largest p-value, was sequentially
removed provided it did not meet the chosen liberal cut-off point for statistical
significance i.e. a p-value > 0.10. With each variable removed, the nested model was
then compared to the previous model based on the corrected AIC value. The model with
the smallest AIC was chosen to be the best model. If the corrected AIC value of the
nested model was within 1% of the previous model, we considered the models equivalent
and choose the more parsimonious model (fewer covariates). The corrected AIC is
calculated16 as:
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corrected!!"# = 2! − 2 ln !"#$%"ℎ!!" +
k
n
ln !"#$%"ℎ!!"

2!(! + 1)
!,
!−!−1

= number of parameters
= number of observations and
= log-likelihood of the model

Corrected AIC was chosen due to the small sample size. Model fit was evaluated using
F-statistic, R2 and adjusted R2 values.
To establish which factors influenced the dependent variable IDWG, independent
variables included PPNa+, dialysis time and frequency, patient age, sex, albumin,
diabetes status, and residual renal function. Patient albumin was included in the model
because of concerns regarding the Gibbs-Donnan effect.17 Model building was performed
to build our first equation, and the F-statistic, R2 and adjusted R2 values were calculated
for resulting model.
To derive an equation defining IDWG, we used multivariable regression analysis.
PPNa+ cannot be used as an independent variable since the post-dialysis plasma Na+ has
to be known. We thus investigated the correlation of PPNa+ to diffusive balance of Na+,
represented by the product of DPNa+ and dialysis time, using Pearson’s correlation
coefficient. A multivariable linear model was then developed leading to Equation 5.2.
The F-statistic, R2 and adjusted R2 values were calculated.
The final predictive model was validated using internal bootstrapping for both
model selection and predictive qualities.18 Multivariable data analysis and bootstrap
validations were conducted using the statistical software R version 2.14.1.19 Bootstrap
validation was conducted by randomly sampling N=86 observations with replacement, to
create the validation sample. Estimates of the residual standard error, mean square
predictive error and mean residual value were calculated by fitting the bootstrap data to
the final predictive model. For each bootstrap sample, we developed new linear models
and estimated the regression coefficients and model properties.

This process was

repeated for 1000 bootstrap samples and the average values of all estimates calculated.
To evaluate the predictive properties of the final equation, the data from each of the 1000
bootstrap samples were fit using the predictive model.
!
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For external validation, we applied equation 5.2 to our current home hemodialysis

patients and compared predicted with actual IDWGs. The variables required for the
predicted were obtained from charts, electronic patient records and dialysis run sheets;
data between August and December 2012 with at least 2 pre-dialysis blood sample results
were taken, averaged and used in the equation 5.2. Actual IDWGs for each dialysis
session in that same period were obtained from run sheets and averaged. Patients who
were in the internal validation were excluded, leaving 24 new patients for the external
validation. The distribution of dialysis modalities (8 SHD, 8 ICHD, 4 FNHD, 4 INHD)
spanned all hemodialysis modalities. Predicted and actual IDWGs were compared by
linear regression and Bland-Altman analyses.20

Figure 5.1: Distribution of Pre-Hemodialysis Plasma Sodium Concentrations
5.3

Results

A total of 2868 matched pre and post-dialysis plasma Na+ values were available, giving
86 sets of time-averaged patient pre and post-dialysis Na+ values (Figures 5.1 and 5.2),
from SHD (n=32), ICHD (n=17) and FNHD (n=37) patients. The majority (87.2%,
75/86) of the pre-dialysis plasma Na+ values were below the dialysate Na+ of 140
mmol/L, while 16.3% (14/86) were below 135 mmol/L. Both pre-dialysis and post-

!

!

84!

dialysis plasma Na+ spanned at least the entire normal range (Table 5.1), with median
values of 137.73 mmol/L and 137.37 mmol/L, respectively.

Figure 5.2: Distribution of Post-dialysis Plasma Sodium Concentrations
The mean, median, and standard deviation of all independent variables were
calculated (Table 5.1), and the range spanned the range for most factors.

DPNa+ = dialysate minus Pre-dialysis plasma sodium concentration; PPNa+ = Postminus Pre-dialysis plasma sodium concentration
Table 5.1: Demographic and Clinical Factors of Patients in
Multivariate Regression Model
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DPNa+ = dialysate minus Pre-dialysis plasma sodium concentration; PPNa+ = Postminus Pre-dialysis plasma sodium concentration
Table 5.2: Univariate Regression Analysis of Interdialytic Weight Gain
in Home Hemodialysis
Using univariable regression analysis for IDWG, the unadjusted p-values and
correlation coefficients for independent factors were calculated (Table 5.2). PPNa+
(R2=20.36%, p<0.001), albumin (R2=9.35%, p=0.020), dialysis frequency (R2=1.74%,
p=0.019) and female sex R2=1.28%, p=0.029) were significantly (p-value > 0.05,
R2>1%) correlated to IDWG. Univariable regression analysis confirmed that PPNa+ was
better than DPNa+ at predicting IDWG (R2 = 20.36% versus 6.66%, p<0.001 versus
0.152).
Equation 5.1 was calculated using multivariable regression analysis, and the same
independent variables, to predict IDWG. Since DPNa+ was less effective at predicting
PPNa+, only PPNa+ was used in our regression model for equation 5.1.
Equation 5.1: IDWG = 5.0694 + 0.17889(PPNa) – 0.1542(frequency) – 0.0145(Age)
– 0.2316(if female) – 0.0457(Albumin) +0.001354 (Dialysis Time)
Where IDWG

!

= interdialytic weight gain, in liters

PPNa+

= (plasma post-dialysis Na+)–(plasma pre-dialysis Na+),in mmol/L

Frequency

= dialysis frequency, in sessions per week

Albumin

= average patient albumin, in g/L
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Dialysis time = Dialysis session time, in minutes
F-statistic
2

= 7.309 on 6 and 79 degrees of freedom (p-value < 0.001),
= 35.69% (adjusted R2 = 30.81%)

R

Standard errors, p-values and 95% confidence intervals for the regression coefficient
estimates are presented in Table 5.3.
Since the post-dialysis plasma Na+ cannot be determined prior to dialysis, we
correlated PPNa+ to the diffusive Na+ balance, represented by the product of DPNa+ and
dialysis time (minutes). The Pearson correlation coefficient between PPNa+ and this
product is 0.4054, suggesting a moderate correlation. In a simple linear regression model
between PPNa+ and the product of (DPNa+) and dialysis time, there was an F-statistic of
16.53 on 1 and 84 degrees of freedom, corresponding to a model p-value of <0.001.
Given the product of DPNa+ and dialysis time was well correlated to PPNa+, a
second equation was developed by fitting a multivariable linear regression model to
IDWG. This second model included all independent variables from equation 5.1, except
PPNa+, which was replaced by the covariate of (DPNa+) times dialysis time. Thus,
equation 5.2 included factors that were all known prior to the dialysis session.
Equation 5.2: IDWG = 5.8178 + 0.00023215 (DPNa+)(Dialysis time) – 0.0107(Age)
- 0.1558(frequency) – 0.2977(if female) – 0.0654(Albumin)
Where IDWG

= Interdialytic weight gain, in Liters

DPNa+

= (Dialysate Na+) – (Pre-dialysis plasma Na+)

Dialysis time = Dialysis session time, in minutes
Frequency

= dialysis frequency, in sessions per week

Age

= years old, of patient

Albumin

= average patient albumin, in g/L

F-statistic

= 4.1940 on 5 and 80 degrees of freedom (p-value = 0.002),

R2

= 20.77% (adjusted R2 = 15.82%)

Standard errors, p-values and 95% confidence intervals for the regression
coefficient estimates are presented in Table 5.3.

The parameter estimates obtained

through the bootstrap sample were all normally distributed. The average (min, max) of

!

!

87!

the residuals was 0.0055 (-0.2207, 0.2449); the average deviation of the bootstrap
samples from the predictive value is close to 0. The average bootstrap residual median
was -0.0091, suggesting that the residuals may have been slightly skewed. The Root
Mean Squared Error (RMSE) for equation 5.2 was 0.7208; this describes the discrepancy
of observations and the estimated model. The bootstrap samples’ average Root Mean
Squared Predictive Error was 0.7218; the predictive power is slightly reduced when
fitting Equation 5.2 to the bootstrap samples. The unadjusted R2 value for the bootstrap
samples was 20.13%, close to the unadjusted R2 value (20.77%) in Equation 5.2.

DPNa+ = dialysate minus Pre-dialysis plasma sodium concentration; PPNa+ = Postminus Pre-dialysis plasma sodium concentration
Table 5.3: Multivariable Regression Analysis to Predict Interdialytic Weight Gain by
Equations 1 and 2
The average R2 value (min, max) for the 1000 created models was 29.62%
(4.80%, 65.85%) and an adjusted R2 of 24.92% (0.10%, 62.79%). The average F-statistic
value was 6.6521 on 5 and 80 degrees of freedom (average p-value = 0.005). The
average occurrence of variable selection is presented in Table 5.4; (DPNa+)(dialysis
duration), sex, albumin and dialysis frequency were in over 80% of the bootstrap
samples, while age, diabetes status and residual renal function (Kr) were in 74%, 73%
and 41%, respectively. The average regression coefficient estimates are also in table 4;
the mean parameter estimates are close to those regression coefficients estimated in
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Equation 5.2. The absolute bias for all covariates is less than 0.08 (except for the
intercept, which shows an absolute bias of 3.3).
The 95% confidence intervals for the bootstrap parameter estimates are also
calculated; the confidence intervals for residual renal function and diabetic status include
0, so these variables were not included in the model. The upper limit for age is close to 0,
but we chose to leave Age in the model since it improved our predictive ability. The
remaining covariates did not include 0 and thus reinforced their inclusion in the model.

DPNa+ = dialysate minus Pre-dialysis plasma sodium concentration; PPNa+ = Postminus Pre-dialysis plasma sodium concentration
Table 5.4: Bootstrap Validation of Predictive Equation for
Interdialytic Weight Gain (Equation 2)
A calibration plot was completed for the external validation cohort (n=24) (Figure
5.3). There were 37 pre-dialysis plasma Na+ measurements available for the external
validation cohort, an average and median of 1.54 and 1.00 for each patient, respectively.
The distribution of IDWG for these patients was determined (Table 5.5), and spanned a
wide range (0.39 to 3.16 liters), with a mean and median of 1.83 and 1.87 Liters. The xaxis represents predictions of IDWG from equation 5.2, and the y-axis represents the
observed IDWG. The solid 450 line represents the performance of the ideal predictive
equation, with thick dashed 450 lines on either side to depict +/- 0.5 Liters. Most (15/24,
62.5%) observations fell within 0.5 L of predicted IDWG, and almost all (22/24, 91.7%)
fell within 1.0 L of predicted IDWG. The line of best fit of the grouped observations (thin
dashed line) was almost superimposed upon the ideal predictive equation (solid line). The
!
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correlation between predicted and observed IDWG (Figure 5.3) was strong (R2 = 0.51,
95% CI 0.25 to 0.75, p<0.001).
A Bland-Altman plot was completed (Figure 5.4). The x-axis represents the average of
predicted (from Equation 5.2) and observed IDWG. The y-axis represents the observed
minus the predicted IDWG. The correlation between difference and average IDWG
(Figure 5.4) was strong (R2 = 0.49, 95% CI 0.18 to 0.74, p<0.001), suggesting that the
difference between observed and predicted IDWG increases with increasing magnitude of
IDWG.

Figure 5.3: Calibration Plot for External Validation Cohort for Equation 5.2
5.4

Discussion

Increased IDWG is associated with hypertension,1,2,6,8 left ventricular hypertrophy and
cardiovascular morbidity and mortality.3 IDWG is influenced by many factors, but salt
balance is one of importance. Dietary salt restriction reduced IDWG, hypertension and
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LVH in a Turkish hemodialysis population, while increased salt intake increased
IDWG.21

Table 5.5: Interdialytic Weight Gain in Patients for External Validation
Factors associated with the dialysis treatment may also influence salt balance. The use of
a dialysate with a Na+ greater than the pre-dialysis plasma Na+ will lead to diffusive Na+
gain by the patient and therefore the need to increase convective removal by
ultrafiltration to restore Na+ balance. Keen and Gotch have shown that the difference
between dialysate Na+ and pre-dialysis plasma Na+ positively correlates with IDWG.22

Figure 5.4: Bland-Altman Plot of Observed Minus Predicted Interdialytic Weight Gain
Versus Average Interdialytic Weight gain
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Several studies have shown that reducing dialysate Na+ concentration will reduce

IDWG and improve outcomes.2-8 The dialysate to patient pre-dialysis Na+ difference is
clearly an important factor in this area. Theoretically, the time and frequency of patient
exposure to this difference should also influence Na+ balance and IDWG but, to date, this
appears to have escaped attention. It may be of relevance that the patients undergoing
nightly hemodialysis had significantly higher IDWG than those treated by short hours
daily hemodialysis in the London Daily/Nocturnal Hemodialysis study when both were
using a dialysate Na+ concentration of 140 mmol/L.10 Whether reductions in dialysate
Na+ concentration are always desirable remains controversial; recent work suggests that
reductions in IDWG need to be achieved in context of other potentially adverse
outcomes.23 Prospective controlled trials are certainly indicated.
The reduction of plasma Na+ over the course of dialysis also influences IDWG.
We have previously shown that progressive reduction of the end dialysis plasma
conductivity (Na+) using a biofeedback control system (DiaControl, Gambro Ab,
Sweden) leads to increased ionic mass removal (Na+) by diffusion and significant
reductions in IDWG, extracellular water and blood pressure.24 Whether the dialysate to
pre-dialysis plasma Na+ difference, or the pre to post dialysis plasma Na+ change more
strongly determines IDWG was uncertain although Hecking and colleagues recently
showed that the latter was more predictive of clinical outcomes.8 The Na+ difference
must be the driving force for the plasma Na+ change but other factors will influence that
change such as the pre-dialysis plasma Na+ and the duration of the dialysis treatment. It
is also possible the plasma albumin via the Gibbs-Donnan effect is of influence.
From the clinical perspective, it is desirable to understand the factors that
influence IDWG. There may be factors that can be modified within the dialysis
prescription. It is accepted that this cannot be finite and that attention must also be given
to psychosocial aspects of salt and water intake. Thus, as part of a Quality Initiative, the
records of our home HD patients were examined creating an ideal study because
treatment modalities included use of extended times and frequency. Furthermore, pre and
post dialysis plasma Na+ levels had been routinely measured.
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Knowing the availability of data we chose as possible independent variables that

influence IDWG: age, sex, diabetic status, residual renal function, duration and frequency
of dialysis treatments, and either DPNa+ or PPNa+. The results of univariable regression
analysis showed that PPNa+ was more predictive than DPNa+, supporting the work of
Hecking.8,12 Diabetic status and residual renal function did not appear to predict IDWG
based on the univariable and multivariable models (Table 5.2).

The remaining

independent variables were used in the multivariable analysis in Equation 5.1. This
indicated significant associations between IDWG and dialysis frequency, PPNa+, plasma
albumin, and age. Female sex was included in this model despite not being statistically
significant because it appeared to improve the model.
A moderate correlation of PPNa+ with the product of dialysis duration and
DPNa+ was found (Pearson coefficient = 0.4054). Thus, a multivariable linear regression
model was developed for Equation 5.2, which determines IDWG as a function of
independent variables known before dialysis, eliminating the post-dialysis plasma Na+
value. These are the product of DPNa+ and dialysis duration, plasma albumin, female
sex, and dialysis frequency. Patient age was also included in this model despite not being
statistically significant, because it generally improved the predictive ability of the model.
An internal bootstrap validation to investigate the predictive properties and model
selection was conducted and showed reproducibility of our model selection, suggesting
that the predictive model covariates in Equation 5.2 are stable for our data. External
validation with a temporally distinct group of new patients showed excellent predictive
ability of Equation 5.2. While Bland-Altman plot (Figure 5.4) shows that IDWG is
underestimated at high IDWG, almost all (91.7%, 22/24) of observed and predicted
IDWG are within 1.0 L, and most (62.5%, 15/25) are within 0.5 L (Figure 5.3). Equation
5.2 does provide clinically important information. The use of a generic dialysate with
Na+ content of 140 mmol/L is not desirable for patients undergoing nightly dialysis for 6
to 8 hours per treatment when most (75/86, 87.2%) of the patients have pre-dialysis
plasma Na+ levels lower (Figure 5.1). A positive Na+ difference of 5 mmol/L, found in
16.3% (14/86) of our patients, will itself account for 0.42 Liters of IDWG (equation 5.2)
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in these circumstances. In most patients, the difference should be zero or even slightly
negative. As a result of this quality initiative study, our local practice will change.
The study is limited by the relatively small number of patients studied and the
retrospective review of laboratory and dialysis run sheet data (e.g. IDWG). Furthermore,
all data points used are aggregates of variable numbers of dialysis and laboratory values
obtainable at variable time periods corresponding to patients’ attendance at clinics. This
may explain why equation 5.1 only provides 30% explanation for IDWG. Post-dialysis
weight is not necessarily the dry weight; this likely influences dietary water and salt
consumption, neither of which can be easily controlled for.. On the other hand, the study
has strengths in that pre and post dialysis plasma Na+ values are available and the fact
that a variety of dialysis modalities were used including short hours daily and long
nightly.
We have created an equation to predict IDWG on the basis of independent factors
readily available before a dialysis session. The modifiable factors include dialysis time
and frequency, and dialysate Na+. Patient sex, age and plasma albumin are also
correlated to IDWG. Further work is required to establish how improvements in IDWG
influence cardiovascular and other clinical outcomes.
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Chapter 6: Clinical Effects of Personalized Dialysate Sodium in Conventional,
Quotidian, and Nocturnal Hemodialysis Patients: A Randomized Crossover Trial.

This manuscript has been submitted for review to Nephrology Dialysis Transplantation.
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Introduction

Cardiovascular death is the leading cause of mortality in hemodialysis patients.1 A
chronic state of volume and pressure overload is a major contributor2-5 leading to
hypertension, left ventricular hypertrophy,6-10 and death.11,12 Considerable research has
evaluated the effect of dialysis frequency and duration on clinical outcomes.6,13-15! It is
well established that longer hemodialysis sessions improve outcomes13,14,16-19 including
mortality.20-22 How this improvement relates to volume and pressure control remains
controversial.
In patients undergoing conventional thrice weekly hemodialysis, pre-dialysis
plasma sodium is stable over time,23,24 and is thus called sodium setpoint (SP). When the
dialysate sodium concentration exceeds the SP, diffusion of sodium into the patient
occurs, and a number of undesirable clinical outcomes result, including increased
interdialytic weight gain (IDWG), blood pressure, and ultrafiltration rate.25-30 These
clinical outcomes are predicted by the magnitude not only of dialysate to pre-dialysis
plasma sodium difference (DPNa+), but also by the post to pre-dialysis plasma sodium
difference (PPNa+).30 However, there are no prospective trials evaluating personalized
dialysate sodium in patients who dialyze more than thrice weekly, or longer than four
hours per session. Quotidian and nocturnal hemodialysis patients are exposed more
frequently and longer to a diffusion difference; how this alters clinical outcomes has not
been prospectively evaluated.
Three objectives were tested in a randomized crossover study. The first objective
was to determine how exposure to a higher DPNa+ altered IDWG, pre- and post-dialysis
blood pressure, and ultrafiltration rate, in a study population that included conventional,
quotidian and nocturnal hemodialysis patients. The second objective was to determine the
effect of dialysis frequency and duration on each of the same clinical outcomes. The third
objective was to establish which of PPNa+ or DPNa+ better predicted clinical outcomes.
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Subjects and Methods

Study Population
All patients in the home hemodialysis program of the Southwestern Ontario Regional
Renal Program were considered. Patients were excluded if they were under the age of 18,
pregnant, or not expected to survive 6 months.
Study Design
A randomized crossover trial design was used (Figure 6.1). The average of the two most
recent monthly pre-dialysis plasma sodium (Pre-Na+) measurements defined the patient’s
sodium setpoint (SP). Patients were randomized to a dialysate sodium (Dial-Na+)
concentration group either 3 mmol/L above (HIGHDialSOD period), or 3 mmol/L below
(LOWDialSOD period) their SP (Figure 1). Dialysate sodium concentration range was
restricted to between 130 and 150 mmol/L, because of concerns of clinical effects. After
100 days, patients crossed over study periods. Patients were followed for another 100 day
period, then the study was completed.
Blood sample collection
Pre-dialysis and post-dialysis blood samples were collected biweekly from the arterial
blood line, using a standard slow blood and stop dialysate method. Locking solution (2
mL of 4% citrate) and a small amount of blood (~2 to 5 mL) are spent prior to blood
collection. The samples are centrifuged and refrigerated until delivered to the laboratory,
within 12 hours of collection. Of interest in this study were pre-dialysis (Pre-Na+) and
post-dialysis (Post-Na+) plasma Na+. Only outpatient blood tests were considered, to
eliminate the confounding effect of acute illness.
Na+ concentration measurement
Plasma Na+ concentration was measured using Roche Modular P Chemistry Analyzer
(Roche Diagnostics, Laval, Quebec, Canada) with ion selective electrodes. Dialysate Na+
concentration was determined using online conductivity measurements in the Fresenius H
series hemodialysis machine.
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Dial Na+ = dialysate Na+ concentration (mmol/L); SP = Pre-dialysis plasma sodium
setpoint (mmol/L); LOWDialSOD = Time period when Dialysate sodium concentration =
SP – 3 mmol/L; HIGHDialSOD = Time period when Dialysate sodium concentration =
SP + 3 mmol/L
Figure 6.1: Randomized Crossover Study Design

Database creation
Demographic, clinical and hemodialysis data were collected from the electronic patient
record (Power Chart by Cerner), home hemodialysis run sheets and the outpatient
hemodialysis unit paper chart. Background factors of interest included patient age, sex,
diabetes status, height (cm), weight (kg), residual renal function (mL/min x 1.73 m2) and
vintage of hemodialysis (days). Residual renal function was calculated as previously
described.31 Hemodialysis records were used to record target weight (kg) and dialysis
frequency (sessions per week) and duration (hours per session) throughout the study.
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Outcomes collected included interdialytic weight gain (IDWG), pre- and post-

dialysis systolic and diastolic blood pressure, and ultrafiltration volume. IDWG was
calculated as the difference between the post-dialysis patient weight and the next dialysis
session’s pre-dialysis patient weight. Dialysate to pre-dialysis plasma sodium (DPNa+)
and post- to pre-dialysis plasma sodium (PPNa+) concentration differences were
recorded. We decided a priori that a minimum of 3 observations per study period would
be required for each outcome, for a patient to be included in the final analysis.
Ethics
Ethics approval was granted by the Western University Health Sciences Research Ethics
Board. Informed written consent was obtained from all patients. The study was conducted
in accordance with the Declaration of Helsinki.
Statistics
Data were analyzed using the Statistical Package for Social Sciences version 19.0. The
mean, median, standard error, and interquartile range were calculated for all background
demographic and clinical factors.
Statistics- Objective 1
Each patient’s outcomes were averaged for each study period. Patients’ outcomes were
then averaged for each study period, and compared using paired two-tailed student Ttests, with an α value of 0.05 considered for statistical significance.
Statistics- Objective 2
Pearson correlation coefficients were calculated between each clinical outcome and
firstly hemodialysis frequency, then hemodialysis duration. Each patient provided two
data points in the analysis, one from each study period. Two-tailed p values with α of
0.05 were used for statistical significance.
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Statistics- Objective 3
Pearson correlation coefficients were calculated between each clinical outcome and
firstly DPNa+, then PPNa+. Two-tailed p values with α of 0.05 were used for statistical
significance.

DPNa+ = dialysate minus Pre-dialysis plasma sodium concentration; PPNa+ = postminus pre-dialysis plasma sodium concentration; HIGHDialSOD = when Dialysate
sodium concentration Setpoint + 3 mmol/L; LOWDialSOD = when Dialysate sodium
concentration = Setpoint – 3 mmol/L
Table 6.1: Number of Observations per Clinical Outcome
6.3

Results

A total of 27 patients completed both study periods. All patients had at least 3
observations for each outcome, and were thus included in data analysis. The mean and
median observations were greater than 40 for all clinical outcomes in both
HIGHDialSOD and LOWDialSOD study periods (Table 6.1). The mean and median
observations were at least 3.0 for both DPNa+ and PPNa+ in both study periods.
The study population’s background factors included an average age of 54.2 years,
with 40.7% female and 33.3% diabetic (Table 6.2). Dialysis frequency averaged 4.4
sessions per week, with a median of 4.0 weekly sessions. Dialysis duration averaged 4.8
hours per session, with a median of 4.0 hours. More than half of study patients had no
residual renal function, with a mean of 0.51 and median 0.00 mL/min.
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Table 6.2: Background Demographic and Clinical Data

Objective 1
IDWG (2.15 vs. 1.90 kg, p=0.002), IDWG as % target weight (2.78 vs. 2.39%, p=0.002),
pre-dialysis systolic (143.3 vs. 138.3 mm Hg, p=0.001), diastolic (78.6 vs. 75.6 mm Hg,
p=0.008) and mean arterial pressure (100.2 vs. 96.5 mm Hg, p=0.003) and post-dialysis
systolic (135.4 vs. 130.0, p=0.04), diastolic (75.8 vs. 72.4, p=0.006) and mean arterial
pressure (95.7 vs. 91.6, p=0.009) were significantly higher in HIGHDialSOD than
LOWDialSOD study period (Table 6.3). No change in target weight, or intradialytic
change in systolic, diastolic or mean arterial pressure was found.
Objective 2
Hemodialysis frequency was inversely related to IDWG% (R = -0.295, Slope = -0.002, P
= 0.034), and positively correlated with post-dialysis diastolic blood pressure (R = 0.366,
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slope = 3.464, p=0.008)(Table 6.4). Hemodialysis duration was inversely correlated with
ultrafiltration rate (R = -0.593, slope = -0.053, p<0.001) and positively correlated with
IDWG (R = 0.562, slope = 0.184, p<0.001) IDWG% (R = 0.507, slope = 0.002, p<0.001)
and intradialytic change in diastolic blood pressure (R = 0.280, slope = 1.127, p=0.044).

HIGHDialSOD = when Dialysate sodium concentration Setpoint + 3 mmol/L;
LOWDialSOD = when Dialysate sodium concentration = Setpoint – 3 mmol/L
Table 6.3: Clinical Endpoints for Home Hemodialysis Patients in HIGHDialSOD
and LOWDialSOD Study Periods

Objective 3
Increased DPNa+ associated with increased IDWG (R = 0.346, slope = 0.001, p=0.012),
pre-dialysis diastolic (R = 0 284, slope = 0.824, p= 0.041) and post-dialysis diastolic (R =
0.325, slope = 1.084, p=0.019) and mean arterial (R = 0.292, slope = 1.030, p=0.036)
blood pressure (Table 6.5). Increased PPNa+ associated with increased IDWG (R =
0.306, slope = 0.001, p=0.029) and post-dialysis systolic (R = 0.181, slope = -0.067,
p=0.049) blood pressure.
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Bolded text denotes statistical significance
Table 6.4: Pearson’s Correlation of the Clinical Outcome with Hemodialysis Frequency
and Duration

6.4

Discussion

In conventional thrice weekly hemodialysis, positive sodium balance is associated with
IDWG, hypertension, left ventricular hypertrophy, and cardiovascular morbidity and
mortality5,26-30,32,33 However, the clinical effects of frequent or prolonged exposure to
higher dialysate sodium concentrations have not been prospectively evaluated. Our study
population included patients on quotidian and nocturnal hemodialysis prescriptions
(Table 6.2). There were a high proportion of females (40.7%) and diabetics (33.3%), and
a wide spectrum of other demographic factors such as age and body habitus.
Furthermore, each patient had multiple measurements of each clinical outcome in each
study period. Thus, our study population was representative of a typical hemodialysis
population, and the clinical outcomes were rigorously evaluated.
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This study confirms that in a patient group with quotidian and nocturnal

hemodialysis patients, personalization of Dial-Na+ higher than SP leads to several
undesirable clinical outcomes, including IDWG, pre- and post-dialysis systolic, diastolic
and mean arterial pressure (Table 6.3). This is consistent with previous trials in thrice
weekly conventional hemodialysis patients.27-30 However, there was no difference in
intradialytic change in systolic, diastolic or mean blood pressure between
HIGHDialSOD.

Bolded text denotes statistical significance; DPNa+= dialysate minus Pre-dialysis plasma
sodium concentration; PPNa+ = post- minus pre-dialysis plasma sodium concentration
Table 6.5: Pearson’s Correlation of Clinical Outcomes with
DPNa+ and PPNa+ Differences

and LOWDialSOD study periods. Previous trials in thrice weekly conventional
hemodialysis patients have demonstrated that low dialysate sodium increases risk for
intradialytic hypotension.34-36 However intradialytic hypotension occurs when increases
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in plasma volume from compartments outside plasma occur slower than hemodialysis
reduces plasma volume.35,37 Our study population had longer hemodialysis duration than
previous trials (mean 4.8 hours, interquartile range 3 -7 hours, Table 6.2). Since plasma
refilling is dependent upon the ultrafiltration rate, longer hemodialysis likely tapered this
effect and decreased the dependence of intradialytic blood pressure changes on dialysate
sodium concentration.
Whether and how dialysis frequency or duration modifies the clinical outcomes
evaluated in this study is of clinical relevance. Our study confirms three important
relationships. Firstly, hemodialysis frequency associates with decreased IDWG% (Table
6.4). Consider the common clinical situation of a patient undergoing thrice weekly
conventional hemodialysis with persistent volume overload and recurrent intradialytic
hypotension. Increased dialysis frequency could improve fluid removal15,38,39 and a
slightly positive DPNa+ difference would protect from intradialytic hypotension.34,36,40
Our data provide evidence to support increasing hemodialysis frequency to decrease
IDWG in such patients. Secondly, hemodialysis duration associates with an increased
IDWG and IDWG%. While one might hypothesize that this relates to more prolonged
exposure to a DPNa+ difference, the difference was positive in the HIGHDialSOD, but
not in the LOWDialSOD study period. Therefore, this could reflect the common practice
of avoiding food and drink during hemodialysis; this would disrupt dietary intake for
conventional and quotidian, but not nocturnal patients. Thirdly, hemodialysis duration
associated with increased intradialytic fall in diastolic blood pressure. Previous research
has consistently shown that increased hemodialysis time decreases ultrafiltration rate and
risk of intradialytic hypotension,22,27,34,41 contrary to this study’s findings. However,
nocturnal hemodialysis patients often sleep during hemodialysis, so post-dialysis blood
pressure is measured in the morning in a relaxed state, unlike the shorter hemodialysis
sessions in conventional dialysis. Therefore, the intradialytic blood pressure change may
relate also to vasomotor tone, rather than ultrafiltration rates.
DPNa+ was superior to PPNa+ in predicting IDWG%, pre-dialysis diastolic, postdialysis diastolic and mean arterial pressure (Table 6.5). These data are in contrast to a
number of trials that suggest PPNa+ to be more predictive.30,42,43 Plasma Na+ approaches
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Dial-Na+ throughout hemodialysis, so intradialytic change in plasma Na+ was predicted
to be less than 3 mmol/L in our study, since Dial-Na+ was randomized to be 3 mmol/L
above (HIGHDialSOD) or below (LOWDialSOD) the SP. Indeed, mean PPNa+ was
quite low in our study (LOWDialSOD PPNa+ = -1.08 mmol/L; HIGHDialSOD PPNa+ =
0.57 mmol/L), so PPNa+ was too small to overcome the lack of precision in the plasma
Na+ measurement. However, use of the PPNa+ difference has the disadvantage of using
Post-Na+ and therefore not being known prior to a hemodialysis session. Knowing that
DPNa+ predicts clinical outcomes better than PPNa+ when Dial-Na+ is 3 mmol/L above
or below the SP provides useful information, and helps guide selection of dialysate
sodium to improve clinical outcomes. Furthermore, it makes measuring Post-Na+
unnecessary so long as Dial-Na+ is within 3 mmol/L of the Pre-Na+.
This study does have limitations. Firstly, we did not record dialysis membrane
surface area or blood glucose,44-47!each of which can impact diffusive sodium balance on
hemodialysis. However, use of a randomized crossover design negated these effects,
since each patient served as their own control, and since these factors were unlikely to
change for any particular patient between study periods. Secondly, our study population
was small. Despite this, an abundance of clinical endpoints and numerous pre- and postdialysis sodium values were available from all patients on multiple dialysis modalities.
We were still able to report important outcomes of statistical and clinical significance.
In conclusion, higher personalized dialysate sodium concentrations lead to
increased interdialytic weight gain, pre- and post-dialysis blood pressure, and
ultrafiltration rates in a patient population that includes conventional, quotidian and
nocturnal hemodialysis patients. While hemodialysis frequency associates with decreased
IDWG%, the opposite relationship is seen with hemodialysis duration. Furthermore,
longer hemodialysis leads to greater falls in diastolic blood pressure, counter to previous
research findings. DPNa+ difference is preferable to PPNa+ to predict clinical outcomes
so long as the Dial-Na+ is personalized within 3 mmol/L of the SP. Further work is
needed to establish the effect of personalizing the dialysate sodium concentrations on
long-term cardiovascular outcomes in quotidian and nocturnal hemodialysis patients.
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Chapter 7: Effect of Personalized Dialysate Sodium Prescription on Plasma Sodium
Concentration and Sodium Setpoint in Conventional, Quotidian and Nocturnal
Hemodialysis.

This chapter has been submitted for review to Nephrology Dialysis Transplantation.
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Introduction

Cardiovascular disease is the leading cause of mortality in hemodialysis patients.1
Chronic volume and pressure overload are major contributing factors, leading to
hypertension, left ventricular hypertrophy and death.2-5 Several strategies to improve
these risk factors have demonstrated success, including dietary sodium restriction,6,7
increasing hemodialysis frequency and duration,8-13 and volume management guided by
bioimpedance.14,15 Of recent relevant interest to this topic is the dialysate sodium
prescription.16-18
Pre-dialysis plasma sodium concentration is relatively stable in thrice weekly
conventional hemodialysis patients, and is thus termed the “sodium setpoint” (SP).19-21
When dialysate sodium concentration is less than SP, increased diffusive sodium removal
occurs, leading to improvement in interdialytic weight gain, pre- and post-dialysis blood
pressure,16,18,22-24 and perhaps also in cardiovascular outcomes and mortality.25,26
However, marked reduction in dialysate sodium concentration gives rise to intradialytic
symptoms including intradialytic hypotension.27,28 This may be mediated by intradialytic
shifts in plasma sodium concentration.27
While effects of personalized dialysate sodium prescription are well described in
conventional thrice weekly hemodialysis patients, these outcomes have not been
prospectively evaluated in quotidian or nocturnal hemodialysis patients. Whether plasma
sodium concentration changes during more frequent or longer hemodialysis sessions is
unknown, and whether such changes impact the sodium setpoint has not been
prospectively evaluated. Three objectives were tested in a randomized crossover study, in
conventional, quotidian and nocturnal home hemodialysis patients. Our first objective
was to determine if personalized dialysate sodium prescription modified plasma sodium
concentration from the start to the end of a hemodialysis session. Our second objective
was to determine if a change in dialysate sodium concentration altered the pre-dialysis
sodium setpoint. Our third objective was to determine if dialysis frequency or duration
modulated changes in either plasma sodium throughout dialysis or sodium setpoint.
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Materials and Methods

Study Population
All patients in the home hemodialysis program of the Southwestern Ontario Regional
Renal Program were considered. Patients were excluded if they were under the age of 18,
pregnant, or not expected to survive 6 months.
Study Design
A randomized crossover trial design was used. The average of the two most recent
monthly pre-dialysis plasma sodium (Pre-Na+) measurements defined the patient’s
sodium setpoint (SP). Patients were randomized to a dialysate sodium (Dial-Na+)
concentration group either 3 mmol/L above (DialNa+ = SP + 3 = HIGHDialSOD), or 3
mmol/L below (DialNa+ = SP – 3 = LOWDialSOD) their SP (Figure 7.1). Dialysate
sodium concentration range was restricted to between 130 and 150 mmol/L, because of
concerns of clinical effects. After 100 days, patients crossed over study periods. Patients
were followed for another 100 day period, then the study was completed.
Blood sample collection
Pre-dialysis and post-dialysis blood samples were collected biweekly from the arterial
blood line, using a standard slow blood and stop dialysate method. Locking solution (2
mL of 4% citrate) and a small amount of blood (~2 to 5 mL) are spent prior to blood
collection. The samples are centrifuged and refrigerated until delivered to the laboratory,
within 12 hours of collection. Of interest in this study were pre-dialysis (Pre-Na+) and
post-dialysis (Post-Na+) plasma Na+. Only outpatient blood tests were considered, to
eliminate the confounding effect of acute illness.
Na+ concentration measurement
Plasma Na+ concentration was measured using Roche Modular P Chemistry Analyzer
(Roche Diagnostics, Laval, Quebec, Canada) with ion selective electrodes. Dialysate Na+
concentration was determined using online conductivity measurements in the Fresenius H
series hemodialysis machine.
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SP = Plasma sodium setpoint (mmol/); DialNa+ = dialysate Na+ concentration (mmol/L);
Blue arrow denotes mean
Figure 7.1: Prospective Randomized Crossover Study Design

Database creation
Demographic, clinical and hemodialysis data were collected from the electronic patient
record (Power Chart by Cerner), home hemodialysis run sheets and the outpatient
hemodialysis unit paper chart. Background factors of interest included patient age, sex,
diabetes status, height (cm), weight (kg), residual renal function (mL/min x 1.73 m2) and
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vintage of hemodialysis (days). Residual renal function was calculated as previously
described.29 Hemodialysis records were used to record dialysis frequency (sessions per
week) and duration (hours per session) throughout the study.
Dialysate to pre-dialysis plasma sodium difference (DPNa+) and post-dialysis
(Post-Na+) to pre-dialysis (Pre-Na+) plasma sodium difference (PPNa+) concentration
were also recorded. We decided a priori that a minimum of 3 observations per DPNa+
and PPNa+ would be required in each of HIGHDialSOD and LOWDialSOD study
periods for a patient to be included in the final analysis.
Ethics
Ethics approval was granted by the Western University Health Sciences Research Ethics
Board. Informed written consent was obtained from all patients. The study was conducted
in accordance with the Declaration of Helsinki.
Statistics
Data were analyzed using the Statistical Package for Social Sciences version 19.0. The
mean, median, standard error, and interquartile range were calculated for all background
demographic and clinical factors.
Statistics- Objective 1
The average pre- and post-dialysis plasma sodium concentrations were calculated for
each patient for each study period. The group average pre- and post-dialysis plasma
sodium concentrations were then compared between HIGHDialSOD and LOWDialSOD,
using paired two-tailed student t-tests with an α value of 0.05 considered for statistical
significance.
Statistics- Objective 2
A change in SP was defined in two ways (Figure 7.2). Firstly, the average Pre-Na+
differed between HIGHDialSOD and LOWDialSOD study periods. Secondly, the slope
of Pre-Na+ (M100) over time differed between study periods. Differences were detected
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using paired two-tailed student t-tests with an α value of 0.05 considered for statistical
significance.

Figure 7.2: Endpoints to Determine Change in Pre-Dialysis Plasma Sodium Setpoint

Statistics- Objective 3
Pearson correlation coefficients were calculated to determine if changes in SP were
modulated by hemodialysis frequency or duration. Y axis included either change in preNa+ or slope of Pre-Na+ from HIGHDialSOD to LOWDialSOD study periods. X axis
included hemodialysis frequency or duration. Slope of correlation was calculated and
two-tailed p values were determined with an α value of 0.05 for statistical significance.
7.3

Results

A total of 27 patients completed both study periods. All patients had at least 3
observations for each of DPNa+ and PPNa+, and were thus included in the final analysis.
Mean and median SP was 138.1 and 138.5 mmol/L, with an interquartile range of 135.5
to 141.0 mmol/L (Figure 7.1, Table 7.1). The study population was an average age of
54.2 years, with 40.7% female and 33.3% diabetic (Table 7.1). Dialysis frequency
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averaged 4.4 sessions per week, with a median of 4.0 weekly sessions. Dialysis duration
averaged 4.8 hours per session, with a median of 4.0 hours. More than half of patients
had no residual renal function, with a mean of 0.51 and median 0.00 mL/min.

Table 7.1: Background Demographic and Clinical Data

Objective 1
Pre-Na+ and Post-Na+ did not differ in HIGHDialSOD study period (137.4 to 137.8
mmol/L, p=0.45). However, plasma Na+ fell throughout dialysis (136.8 to 135.0 mmol/L,
p=0.002) in LOWDialSOD study period (Figure 7.3).
Objective 2
Pre-Na+ sodium setpoint decreased from HIGHDialSOD to LOWDialSOD study period
(137.4 to 136.8 mmol/L, p=0.03) (Table 7.2). The slope of Pre-Na+ (M100) also
decreased from HIGHDialSOD to LOWDialSOD study periods (0.014 to -0.015
mmol/L/day, p=0.009).
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HIGHDialSOD= when Dialysate sodium concentration is 3 mmol/L greater than predialysis plasma sodium “setpoint”; LOWDialSOD=when Dialysate sodium concentration
is 3 mmol/L lower than pre-dialysis plasma sodium “setpoint.”
Figure 7.3: Pre and Post-Dialysis Plasma Sodium Concentration with High (Period 1)
or Low (Period 2) Personalized Dialysate Sodium

Objective 3
The change in Pre-Na+ across study periods was not correlated to hemodialysis
frequency (R = 0.264, p=0.193) or duration (R = 0.032, p=0.877) (Table 7.3). Likewise,
the change in slope of Pre-Na+ across study periods was not correlated to hemodialysis
frequency (R = 0.172, p=0.401) or duration (R=0.067, p=0.745).
7.4

Discussion

Reduction in dialysate sodium concentration can reduce IDWG, blood pressure and
negative cardiovascular outcomes.16,18,23 However, it may also give rise to intradialytic
hypotension,27,28 mediated by intradialytic shifts in plasma sodium concentration.27
Whether personalized dialysate sodium prescription associates with intradialytic shifts in
plasma sodium in quotidian or nocturnal hemodialysis patients is previously unreported.
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HIGHDialSOD = Dialysate sodium concentration 3 mmol/L higher than pre-dialysis
sodium setpoint; LOWDialSOD = Dialysate sodium concentration 3 mmol/L lower than
pre-dialysis sodium setpoint. Bolded text denotes statistically significant changes.
Table 7.2: Difference in Absolute and Slope of Pre-Dialysis Plasma Sodium Setpoint
with Two Personalized Dialysate Sodium Concentrations

P = p value; R = Pearson’s correlation coefficient
Table 7.3: Effect of Hemodialysis Frequency and Duration on Change Across Study
Periods in Absolute and Slope of Pre-Dialysis Sodium Setpoint
This randomized crossover study included patients with a spectrum of dialysis
frequency (mean = 4.4, interquartile range = 3 to 6 sessions per week) and duration
(mean = 4.8, interquartile range 3-7 hours)(Table 7.1). There was a high number of
females (40.7%) and diabetics (33.3%) and a wide spectrum of other demographic and
clinical factors such as blood pressure, age and body habitus. Every patient had at least 3
recordings of PPNa+ and DPNa+ during each study period. The sodium setpoint (SP)
varied widely in our study population (interquartile range 135.5 to 141.0, Table 1 and
Figure 7.1). Thus, our study population was representative of a typical hemodialysis
population, and outcomes were evaluated with rigor.
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While the HIGHDialSOD plasma sodium did not change over dialysis (137.4 to

137.8 mmol/L, p=0.45), there was a significant decrease from Pre-Na+ to Post-Na+ in the
LOWDialSOD study period (136.8 to 135.0 mmol/L, p=0.002)(Figure 7.3). This is
consistent with Suckling et al’s recent work.27 While the magnitude of intradialytic
plasma sodium change was small in our study, there is still reason for concern. Firstly,
intradialytic decrease in plasma sodium is linked to intradialytic hypotension,27 which
independently increases risk of death.28 Secondly, ignoring patient-specific SP by facility
level decreases in dialysate sodium concentrations will lead to significantly negative
DPNa+ differences in some patients. Again, this increases the risk of intradialytic
hypotension. Ultimately, selection of dialysate sodium should be personalized to the
patient to limit adverse outcomes of a very positive DPNa+, while simultaneously
avoiding the complications of intradialytic plasma sodium shifts from a negative DPNa+;
this can only be done by regularly following the Pre-Na+ and adjusting the Dial-Na+
accordingly.
While Pre-N+ is stable as a “setpoint” in thrice weekly conventional hemodialysis
patients,19-21 this has not been prospectively evaluated in quotidian or nocturnal
hemodialysis patients. A retrospective study by our research group found that conversion
from thrice weekly conventional to quotidian hemodialysis associated with a reduction in
SP, when DPNa+ was neutral or negative.30 We confirm a change in SP prospectively in
this study, as mean pre-Na+ (137.4 vs. 136.8 mmol/L, p=0.03) and slope of pre-Na+
(0.014 vs. -0.015 mmol/L/day, p=0.009)(Table 2) differ between HIGHDialSOD and
LOWDialSOD study periods. While the magnitude of the change in pre-Na+ is small,
this is both statistically and clinically important. Firstly, decreases in sodium setpoint are
independently associated with increased mortality.31,32 Secondly, hemodialysis units that
use facility wide dialysate sodium prescriptions will lead many patients to having highly
negative DPNa+ and thus more exaggerated decreases in SP. Thirdly, in units that
personalize dialysate sodium by following Pre-Na+, repeated decreases in Dial-Na+ to
maintain a negative DPNa+ could cause repeated and undesirable decreases in SP.
Finally, this raises the possibility that hemodialysis prescription might be modified to
increase SP in vulnerable patients. More research will be required to determine the
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pathophysiologic mechanism of a change in SP in these patients, and to determine the
impact on cardiovascular outcomes.
There are limitations to this study. Firstly, we did not measure blood glucose,
lipids or paraprotein levels, each of which can impact plasma sodium measurement.33-35
However, use of a randomized crossover study design negated these effects, since each
patient served as their own control, and since these factors were unlikely to change for
any particular patient between study periods. Secondly, our study population was small.
However, our patients are highly compliant, having participated in multiple previous
research trials.12,13 This enabled the recording of numerous pre- and post-dialysis sodium
values from all patients on multiple hemodialysis modalities. We were thus able to report
statistically and clinically significant outcomes.
In

conventional,

quotidian

and

nocturnal

hemodialysis

patients,

the

personalization of Dial-Na+ to lower than the SP decreases plasma sodium throughout
hemodialysis. Furthermore, Dial-Na+ can modify the Pre-Na+ “setpoint.” Further
research is needed to determine the effect on cardiovascular morbidity and mortality.
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General Discussion and Conclusions

The most common cause of death in patients with end stage kidney disease is
cardiovascular (Figure 1.1).1 A major contributor is the chronic state of volume and
pressure overload,2-8 which leads to left ventricular hypertrophy9-17 and death.18,19 Of
critical importance is the total sodium balance during a hemodialysis session,8,20-24 which
is determined by the sum of diffusion and osmosis.
Diffusive balance during hemodialysis reflects the effects of several factors
(Equation 1.4). Many factors are not modifiable, such as dialyzer hollow fiber radius
(Chapter 1.1.1.1 and 1.1.1.2), length (Chapter 1.1.1.1 and 1.1.1.3) or thickness (Chapter
1.1.1.4). Likewise, several factors must be maintained within a narrow range, such as
dialysate temperature (Chapter 1.1.1), patient hematocrit and albumin (Chapter 1.1.1.8).
On the other hand, the hemodialysis frequency and duration can be modified, as can the
difference between dialysate and pre-hemodialysis plasma sodium concentrations
(DPNa+). In Chapter 4, using retrospective data, we confirm that the post- to pre-dialysis
plasma sodium difference (PPNa+) is superior to DPNa+ to predict clinical outcomes
such as interdialytic weight gain, blood pressure, and the change in blood pressure during
a hemodialysis session.25 However, the opposite was found using prospective data
(Chapter 6). This could be because the magnitude of the DPNa+ and PPNa+ difference
was much smaller as the study design involved personalization of the dialysate sodium
within 3 mmol/L from the pre-hemodialysis plasma sodium concentration, or “setpoint.”
This is an important observation for three reasons. Firstly, there is no clinical advantage
to current practice of performing pre- and post-hemodialysis plasma sodium
concentrations, so long as the dialysate sodium concentration is within 3 mmol/L of the
setpoint. Secondly, the dialysate sodium concentration can be chosen before a dialysis
session, making it modifiable, unlike the post-dialysis plasma sodium concentration.
Finally, it confirms that the selection of dialysate sodium concentration greater than the
setpoint leads to undesirable increases in interdialytic weight gain and blood pressure.
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Selection of dialysate sodium concentration within 3 mmol/L of the setpoint

requires knowing it will remain stable over time. Previous trials confirm setpoint stability
in thrice weekly conventional hemodialysis.26-28 However, the setpoint is not stable in a
patient population of quotidian, conventional and nocturnal hemodialysis patients,
retrospectively in Chapter 3,29 nor prospectively in Chapter 7. Use of a Dial-Na+ of 140
mmol/L led to decrease in setpoint in patients with pre-hemodialysis plasma sodium
concentration greater than or equal to 140 mmol/L (Chapter 3). Furthermore,
personalization of dialysate sodium concentration 3mmol/L less than the SP leads to a
decrease in setpoint (Chapter 7). Given that low pre-hemodialysis plasma sodium
concentration independently predicts mortality,30 this is an important observation. This
gives pause to the practice of increasing diffusive sodium loss by using a dialysate
sodium concentration lower than the pre-hemodialysis plasma sodium concentration.
Further research is required to determine if intentional increases in setpoint are possible
or beneficial for cardiovascular and all-cause morbidity and mortality.
The factors that determine interdialytic weight gain are important to delineate, so
that they may be modified prior to a hemodialysis session. In Chapter 5, those variables
were determined to be dialysis time, frequency and dialysate sodium.31 Furthermore,
several unmodifiable factors were important, including patient sex, age and serum
albumin. Ultimately, an equation was created that was validated internally using
bootstrapping and externally using a temporally distinct patient subset. Our research
group is currently prospectively validating this equation, with a dataset that includes
patients with a variety of dialysate sodium concentrations, dialysis durations and
frequencies, and residual renal functions. We hope to finish this work by June, 2015.
As plasma water is removed from a patient, plasma hematocrit increases during
hemodialysis, causing an increase in blood viscosity (Section 1.1.1.8). As interdialytic
weight gain increases, the requirement for fluid removal during hemodialysis also
increases, and thus also blood viscosity. Since increases in blood viscosity lead to
decreased diffusive sodium loss (Equation 1.5), one might hypothesize that the increased
mortality from higher interdialytic weight gain occurs partially due to decreased solute
clearance towards the end of hemodialysis, when blood viscosity reaches its maximum.
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As our equation is validated in more populations, we will need to establish the effect of
blood viscosity on solute clearance and mortality. This hypothesis evidently needs further
evaluation.
While hemodialysis equipment modification was not the focus of this thesis, it is
noteworthy that the design of materials already considers Poiseuille’s Law (Equation
1.7). Specifically, it is desirable not to have increased pressure drop across the hollow
fiber of the dialysis membrane; this prevents backfiltration of the dialysate, which is
undesirable (Section 1.1.1.2 and 1.1.1.3). Even a small (10%) increase in hollow fiber
radius causes a large (46%) decrease in blood flow resistance. So long as the blood flow
is constant, this leads to a significant increase in the pressure drop over a hollow fiber,
which again leads to backfiltration of dialysate (Equation 1.8). Similarly, a long hollow
fiber would increase pressure drop (Equation 1.7), but would also increase surface area
for diffusion (Equation 1.6). It is thus inevitable that advances in hemodialysis
technology will play a key role in optimizing safe diffusive and osmotic sodium removal
in the years to come. In light of these future trials designed to improve hemodialysis
technology, our work will play a key role in assuring their safe and effective design.
Specifically, it will be essential to monitor the pre-dialysis plasma sodium setpoint to
assure stability. Use of the DPNa+ and PPNa+ concentration differences under particular
circumstances that have been defined by our studies will also be important. Finally,
focusing on factors that are modifiable for patients’ interdialytic weight gain will improve
the yield of such studies.
Hemodialysis prescription continues to be an essential consideration in improving
cardiovascular mortality in patients with end stage kidney disease. Future research will
need to combine dialysis prescription with monitoring measurements such as
bioimpedance. While low dialysate sodium improves clinical outcomes such as
interdialytic weight gain and blood pressure, it is associated with decrease in setpoint in
patients on frequent or longer hemodialysis treatments. It is thus proposed that sodium
balance-neutral or slightly positive is a preferable choice, ensuring quality dialysis with
minimal sodium gain-related complications. Only with careful monitoring of pre-dialysis
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setpoint and personalized selection of dialysis frequency, duration and dialysate sodium
concentration can outcomes be optimized.
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! Western University Clinical Investigator Program. (Winner July 2012 – present)
! Program of Experimental Medicine, Western University. (Grant awardee)
! Canadian Association of Nephrology, Trainee Research Award. (National Finalist
April, 2013)
! Kristin Sivertz National Resident Leadership Award (National Finalist June, 2012)
! Chief Nephrology Fellow (July 2011-June 2012)
! AMGEN Young Investigators Award (Finalist, February 2011)
! Canadian Society of Internal Medicine annual Research Award (National Finalist,
2010)
! University of Calgary Internal Medicine research day (top clinical research project in
2010, top research project honorable mention 2009, top quality assurance and
quality improvement research project in 2008 and 2009).
! University of Calgary CANMEDS “model of Professionalism” (for all residents in
Calgary, 2009)
! University of Calgary Internal Medicine, “Most likely to cover call” award (2009)
! Top Senior Resident, Rockyview General Hospital, Calgary. (July 2008 to June 2009)
! Dean’s List, National University of Ireland (2003, 2004, 2005, 2006 and 2007)
! University Scholar, National University of Ireland (2004 and 2006)
! McGill Anatomy and Cell Biology student scholarship (Sept 1999 to June 2001)
! Ireland Power-Lifting National Champion (2004, 2005)
! World Championships Powerlifting Competitor (Second place overall, November
2005)
! European Championships Powerlifting (First Place, November 2005)
! University of Waterloo Federation of Students Leadership Award (September 1998)
! University of Waterloo Circle of Volunteerism Award (April 1999)
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PUBLISHED WORKS:
Books:
Thomson BK, Acedillo RR. Critical References Nephrology- First Edition. CreateSpace
2013. Available for review and purchase at: www.amazon.com (search “best evidence
nephrology”).
Invited Oral Presentations:
1. Thomson BK, Dixon S, Huang SH, Leitch R, Heidenheim AP, Suri R, Chan C,
Lindsay RM. Modifiable variables affecting interdialytic weight gain include dialysis
time, frequency and dialysate sodium. Canadian Society of Nephrology for April, 2013
(Montreal, Canada).
2. Identification and Management of common nephrological emergencies. Invited by:
Palestinian Health Authority for Feb 2-24, 2013.
3. Thomson BK, MacRae JM, Barnieh L, Zhang J, MacKay E, Manning MA,
Hemmelgarn BR. Evaluation of an electronic warfarin nomogram for anticoagulation of
hemodialysis patients. AMGEN Young Investigators Forum, National Finalist
Presentation, 2011 (Montreal, Canada).
4. Thomson BK, MacRae JM, Barnieh L, Zhang J, MacKay E, Manning MA,
Hemmelgarn BR. Evaluation of an electronic warfarin nomogram for anticoagulation of
hemodialysis patients. Canadian Society of Internal Medicine, National Finalist
Presentation, 2010 (Vancouver, Canada).
Peer-Reviewed Journal Articles:
Submitted, under review
1. Thomson BK, Li L, Leitch RE, Spanner ED, Kamphuis S, Lindsay RM. Clinical
effects of personalized dialysate sodium in conventional, quotidian and nocturnal
hemodialysis patients: A randomized crossover trial. Submitted and under review to:
Nephrology Dialysis Transplantation.
2. Thomson BK, Li L, Leitch RE, Spanner ED, Kamphuis S, Lindsay RM. Effect of
Personalized Dialysate Sodium Prescription on Plasma Sodium Concentration and
Sodium Setpoint in Conventional, Quotidian and Nocturnal Hemodialysis. Submitted and
under review to: Nephrology Dialysis Transplantation.
In Press
1. Thomson BK, Nolin TD, Velenosi TJ, Feere DA, Knauer MJ, Asher LJ, House AA,
Urquhart BL. Effect of Chronic Kidney Disease and Dialysis Modality on Exposure to
Drugs Cleared by Non-Renal Mechanisms. Accepted for publication in: American
Journal of Kidney Diseases: Contribution = 30%
2. Thomson BK, Clark WF, Hladunewich M, Joseph G, Patel A, Blake PG, Eastabrook
G, Matsui D, Sharma A, House A. Maternal, Pregnancy and Fetal Outcomes in de novo
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Anti-glomerular Basement Membrane Antibody Disease in Pregnancy: A Systematic
Review. Accepted for publication in: Clinical Kidney Journal: Contribution = 80%.
3. Thomson BK, Huang SH, Lindsay RM. The Choice of Dialysate Sodium is Influences
by Hemodialysis Frequency and Duration: What should it be and for what modality?
Accepted for publication in: Seminars in Dialysis: Contribution = 80%.
4. Huang SH, Filler G, Thomson BK, Blake PG, Lindsay RM. Elevated Blood Lead
Levels in Home Hemodialysis Patients: Are They Toxic or Acceptable? Accepted for
publication in: Blood Purification: Contribution = 10%.
5. Huang SH, Laporte S, Thomson BK, Shah S, Filler G, Lindsay RM. What is Single
Needle Cannulation Hemodialysis: Is it Adequate?” Accepted for publication in: Blood
Purification: Contribution = 5%
In circulation
6. Juma S, Thomson BK, Lok CE, Clase CM, Blake PG, Moist L. Warfarin use in
hemodialysis patients with atrial fibrillation: decisions based on uncertainty. BMCNephrology 2013; 14: 174 Contribution :50%.
7. Thomson BK, Huang SH, Chan CT, Urquhart B, Skanes A, Lindsay RM. Nocturnal
home hemodialysis associates with improvement of electrocardiographic features linked
to sudden cardiac death. ASAIO J 2014; 60(1): 99-105. Contribution: 85%.
8. Marek C, Thomson BK, Shoker A, Luke P, Moser M. The prognostic value of time
needed on dialysis (TND) in patients with delayed graft function. Nephrol Dial
Transplant 2014; 29(1), 203-208. Contribution: 40%.
9. Thomson BK, Moser M, Marek C, Bloch M, Weernink C, Shoker A, Luke PP.
Peritoneal Dialysis versus Hemodialysis in Patients with Delayed Graft Function. Clin
Transplant 2013; 27(6): E709-14. Contribution: 80%.
10. Thomson BK, Momciu B, Huang SH, Chan CT, Urquhart B, Skanes A, Krahn A,
Klein G, Lindsay RM. ECG Machine QTc intervals are inaccurate in hemodialysis
patients. Nephron Clin Pract 2013; 124(1-2): 113-118. Contribution: 85%.
11. Thomson BK, Huang SH, Leitch RE, Dixon S, Heidenheim P, Suri RS, Chan CT,
Lindsay RM. Pre to post-dialysis plasma sodium change better predicts clinical outcomes
than dialysate to plasma sodium gradient in quotidian hemodialysis. Hemodial Int 2013
April 3 (Epub ahead of print). Contribution: 85%.
12. Thomson BK, Dixon SN, Huang SH, Leitch RE, Suri RS, Chan CT, Lindsay RM.
Modifiable variables affecting interdialytic weight gain include dialysis time, frequency
and dialysate sodium. Hemodial Int 2013 Jun 18 (Epub ahead of print). Contribution:
75%.
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13. Thomson BK, Huang SH, Chan CT, House AA, Lindsay RM. Plasma Sodium
Setpoint: Is it Constant or Changed by Hemodialysis Prescription? ASAIO J 2013 Jul 26
(Epub ahead of print). Contribution: 85%.
14. Thomson BK, Momciu B, Huang SH, Chan CT, Urquhart BL, Skanes AC, Krahn
AD, Klein GJ, Lindsay RM. Frequent Nocturnal Hemodialysis Associates with
Improvement of Prolonged QTc Intervals. Nephron Clin Pract 2013 Jul 11: 123 (1-2) 7482. Contribution: 80%.
15. Clase CM, Holden RM, Sood MM, Rigatto C, Moist LM, Thomson BK, Mann JF,
Zimmerman DL. Should patients with advanced chronic kidney disease and atrial
fibrillation receive chronic anticoagulation? Nephrol Dial Transplant. 2012;27(10):371924. Contribution: 10%.
16. Thomson BK, Zhang J, MacRae J, MacKay E, Manning M, Hemmelgarn B.
Evaluation of an electronic warfarin nomogram for anticoagulation of hemodialysis
patients. BMC Nephrol. 2011. 12: 46. Contribution: 75%.
17. Thiesen A, Tappenden KA, McBurney MI, Clandinin MT, Keelan M, Thomson BK,
Drozdowski LA, Wild G, Thomson ABR. Dietary lipids alter the effect of steroids on the
transport of Fructose Following intestinal resection in rats. Dig Dis Sci. 2008. 53: 212639. Contribution: 15%.
18. Park EJ, Suh M, Thomson BK, Ma DWL, Ramanujam K, Thomson ABR, Clandinin
MT. Dietary Ganglioside inhibits acute inflammatory signals in intestinal mucosa and
blood induced by systemic inflammation of Escherichia coli lipopolysaccharide. Shock
2007; 28(1), 112-117. Contribution: 15%.
19. Park EJ, Suh M, Thomson BK, Thomson ABR, Ramanujam KS, Clandinin MT.
Dietary ganglioside decreases cholesterol content, caveolin expression and inflammatory
mediators in rat intestinal microdomains. Glycobiology 2005; 15 (10), 935-942.
Contribution: 25%.
20. Thomson AB, Drozdowski L, Iordache C, Thomson BK, Vermeire S, Clandinin MT,
Wild G. Small bowel review: Diseases of the small intestine. Dig Dis Sci. 2003
Aug;48(8):1582-99. Contribution: 15%.
21. Thomson AB, Drozdowski L, Iordache C, Thomson BK, Vermeire S, Clandinin MT,
Wild G. Small bowel review: Normal physiology, part 2. Dig Dis Sci. 2003
Aug;48(8):1565-81. Contribution: 15%.
22. Thomson AB, Drozdowski L, Iordache C, Thomson BK, Vermeire S, Clandinin MT,
Wild G. Small bowel review: Normal physiology, part 1. Dig Dis Sci. 2003
Aug;48(8):1546-64. Contribution: 15%.
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23. Thiesen AL, Tappenden KA, McBurney MI, Clandinin MT, Keelan M, Thomson BK,
Wild GE, Thomson AB; Cell and Molecular Biology Collaborative Network in
Gastrointestinal Physiology. Dietary lipids alter the effect of steroids on transport of
glucose after intestinal resection: Part II. Signalling of the response. J Pediatr Surg. 2003
Apr;38(4):575-8. Contribution: 15%.
24. Thiesen AL, Tappenden KA, McBurney MI, Clandinin MT, Keelan M, Thomson BK,
Wild GE, Thomson AB. Dietary lipids alter the effect of steroids on the transport of
glucose after intestinal resection: Part I. Phenotypic changes and expression of
transporters. J Pediatr Surg. 2003 Feb;38(2):150-60. Contribution: 15%.
25. Thiesen A, Wild GE, Tappenden KA, Drozdowski L, Keelan M, Thomson BK,
McBurney MI, Clandinin MT, Thomson AB. The locally acting glucocorticosteroid
budesonide enhances intestinal sugar uptake following intestinal resection in rats. Gut.
2003 Feb;52(2):252-9. Contribution: 15%.
26. Thiesen A, Wild GE, Tappenden KA, Agellon LB, Drozdowski L, Keelan M,
Thomson BK, McBurney MI, Clandinin MT, Thomson AB. Intestinal resection- and
steroid-associated alterations in gene expression were not accompanied by changes in
lipid uptake. Digestion. 2002;66(2):112-20. Contribution: 15%.
27. Thiesen A, Tappenden KA, McBurney MI, Clandinin MT, Keelan M, Thomson BK,
Agellon L, Wild G, Thomson AB. Dietary lipids alter the effect of steroids on the uptake
of lipids following intestinal resection in rats. Dig Dis Sci. 2002 Aug;47(8):1686-96.
Contribution: 15%.
Poster Presentations
American Society of Nephrology, November, 2013 (Atlanta, United States)
1. Urquhart BL, Thomson BK, Nolin, TD, Velenosi TJ, Feere DA, Knauer MJ,
Asher LJ and House AA. Midazolam and Fexofenadine Pharmacokinetics are
Altered in Patients with Chronic Kidney Disease (abstract 2409). Contribution:
30%.
2. Thomson BK, Momciu B, Huang SH, Chan CT, Urquhart BL, Skanes AC, Krahn
AD, Klein GJ, Lindsay RM. Frequent Nocturnal Hemodialysis Associates with
Improvement of Prolonged QTc Intervals (abstract 4966). Contribution: 80%.
3. Thomson BK, Huang SH, Leitch RE, Lindsay RM. Effect of Personalize
Dialysate Sodium on Clinical Outcomes and Sodium Setpoint Stability, in
Patients on Nocturnal and Frequent Hemodialysis Modalities (abstract 4996).
Contribution: 80%.
Canadian Society of Nephrology, April, 2013 (Montreal, Canada)
4. Thomson BK, Huang SH, Leitch RE, Dixon S, Heidenheim P, Suri RS, Chan CT,
Lindsay RM. Pre to post-dialysis sodium Gradient more predictive than Dialysate
to Pre-dialysis sodium Gradient for Clinical Outcomes in Quotidian
Hemodialysis. Contribution: 85%.
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5. Thomson BK, Huang SH, Chan C, House A, Lindsay RM. Plasma Sodium
Setpoint; Is it constant or Changed by Hemodialysis Prescription? Contribution:
85%.
6. Thomson BK, Huang SH, Chan CT, Skanes AC, Krahn AD, Klein GJ, Lindsay
RM. Dialysis Frequency and Duration: Effect on Electrocardiographic QTc
intervals. Contribution: 85%.

Canadian Association of Transplantation, March 13, 2013 (Banff, Canada)
7. Marek C, Thomson BK, Bloch M, Shoker A, Luke P, Moser M. The prognostic
value of “Time Needed on Dialysis” in patients with Delayed Graft Function
(DGF). Contribution: 40%.
8. Thomson BK, Moser M, Marek C, Bloch M, Weernink C, Shoker A, Luke P.
Peritoneal Dialysis versus Hemodialysis in Patients with Delayed Graft Function.
Contribution: 80%
American Society of Nephrology, 2012 (San Diego, United States of America)
9. Thomson BK, Dixon S, Huang SH, Leitch R, Heidenheim AP, Suri R, Chan C,
Lindsay RM. Modifiable variables affecting interdialytic weight gain include
dialysis time, frequency and dialysate sodium. Contribution: 75%.
Canadian Society of Nephrology, 2012 (St. Johns, Canada)
10. Juma S, Thomson BK, Lok CE, Clase CM, Blake PG, Moist L. Canadian Society
of Nephrology Survey confirms clinical equipoise for using warfarin in
hemodialysis patients with atrial fibrillation. Contribution: 50%.
American Society of Nephrology, 2011 (Philadelphia, United States of America)
11. Juma S, Thomson BK, Lok CE, Clase CM, Blake PG, Moist L. Canadian Society
of Nephrology Survey confirms clinical equipoise for using warfarin in
hemodialysis patients with atrial fibrillation. Contribution: 50%.
American Society of Nephrology, 2010
12. Thomson BK, MacRae JM, Barnieh L, Zhang J, MacKay E, Manning MA,
Hemmelgarn BR. Evaluation of an electronic warfarin nomogram for
anticoagulation of hemodialysis patients. Contribution: 75%.
Canadian Society of Nephrology, 2010
13. Thomson BK, MacRae JM, Barnieh L, Zhang J, MacKay E, Manning MA,
Hemmelgarn BR. Evaluation of an electronic warfarin nomogram for
anticoagulation of hemodialysis patients. Contribution: 75%.

